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I 
ABSTRACT 
Cutaneous Human Papillomaviruses (cuHPVs) cause the most common HPV 
infections and are frequently detected and tend to persist asymptomatically in the 
skin of the general population. The cuHPV types are mainly represented by the beta 
and gamma genera, of which the beta-HPV infections has been suspected to be 
involved in the development of non-melanoma skin cancers (NMSC), besides well-
known risk factors, such as immunosuppression and ultraviolet (UV) light radiation. 
The ability of cuHPVs to persist in the absence of disease, i.e latency, has long being 
suspected. In humans, administration of immunosuppressive drugs such as 
cyclosporine A (CsA) to organ transplant recipients (OTRs) and/or sun exposures are 
risk factors that have been proposed to activate cuHPV latent infections leading to 
apparent tumors.  
Cutaneous infection of New Zealand White rabbits with CRPV represents an 
attractive animal model that enables in vivo investigation of cuHPV infection. In this 
study, we employed the CRPV/rabbit model to investigate whether latent cuHPVs 
infections are controlled by the immune system and/or UV radiation. We observed 
that a level of one viral DNA copy per 200 to 1000 cells can be detected in 88% of 
the latently infected skin sites more than 14 months post infection (p.i.). Viral copy 
numbers dramatically increased, when latent skin samples were explanted in tissue 
culture. Low-dose UV alone showed no significant effect on viral latency. We 
observed an increase in viral genome copy numbers in latently infected skin sites 
upon immunosuppression. Although the appearance of three papillomas on only one 
rabbit in latent period was likely to be activated by immunosuppression, the majority 
of latently infected sites showed no papilloma formation. Surprisingly, the 
combination of immunosuppression and UVA + UVB radiation showed no significant 
difference compared to immunosuppression alone. 
During the course of our latency experiment, we observed a dramatic increase of pre-
existing papilloma growth upon CsA-based immunosuppression. We demonstrated 
that the fast-growing papillomas were not associated with the levels of viral DNA 
copies or viral gene expressions. T-cell counts and T-cell associated cytokines were 
significantly decreased due to systematic immunosuppression. Interestingly, the pro-
inflammatory cytokines such as IL-8 and IL-1β were significantly upregulated 
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specifically in the fast growing papillomas. Although, it has been shown that CsA can 
induce cell proliferation and tumorigenesis independent of host immune system, it 
has been widely used as an immunosuppressant in previous PV-related studies, and 
the side effect of CsA on PV-induced tumorigenesis has not been investigated. Our 
results here indicate that the proliferation of rabbit-derived cells was increased upon 
CsA treatment. 
In conclusion, we have established an outbred CRPV/rabbit model for the study of 
latent infections with cutaneous PVs which allows investigating factors controlling the 
latent state.  
We demonstrated that short-term immunosuppression increased latent viral genome 
copy numbers, but did not lead to new papilloma formation at majority of latently 
infected sites. Low-dose UV alone showed no significant effect on viral latency. The 
combination of short-term immunosuppression and UV radiation showed no 
significant difference compared to immunosuppression alone. However, it is still 
possible that the reactivation of latent viral infection may require longer-term 
systematic immunosuppression or multiple UV radiations. 
In addition, we demonstrated that CsA-based immunosuppression facilitates pre-
existing papilloma growth likely via reduction of immune surveillances, upregulation 
of pro-inflammatory cytokines such as IL8 and IL-1β, and maybe CsA-related 
tumorigenesis. 
Our findings here may provide implications for the clinic treatment of CsA-based 
immunosuppression of OTRs associated with cuHPV infection. 
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ZUSAMMENFASSUNG 
Infektionen mit kutanen Papillomviren (cuHPVs) sind sehr häufig in der 
Allgemeinbevölkerung, wo sie zumeist symptomlos in der Haut über längere Zeit 
persistieren und nachgewiesen werden können. Die cuHPV-Typen werden 
hauptsächlich durch die Beta- und Gamma-Gattungen repräsentiert, von denen, 
neben bekannten Risikofaktoren wie Immunsuppression und Ultraviolette (UV) 
Strahlung, die Beta-HPV-Infektionen vermutlich an der Entwicklung von Nicht-
Melanom-Hautkrebs (NMSC) beteiligt sind. Die Fähigkeit der cuHPVs, in 
Abwesenheit von Läsionen zu persistieren, d.h. ein Latenzzustand, wurde in der 
Literatur immer wieder diskutiert. Beim Menschen wurde die Verabreichung von 
immunsuppressiven Medikamenten wie Cyclosporin A (CsA) bei 
Organtransplantationsempfängern (OTRs) sowie UV-Strahlung als Risikofaktoren 
vorgeschlagen, die zur Aktivierung latenter cuHPV Infektionen und somit zur 
Tumorbildung führen können.  
Die kutane Infektion von Weißen Neuseeländer Kaninchen mit CRPV (Cottontail 
Rabbit Papillomavirus) ist ein ideales Tiermodell, was die in vivo Untersuchung der 
cuHPV-Infektion ermöglicht. In dieser Arbeit wurde dieses Modell eingesetzt, um zu 
untersuchen, ob latente cuHPVs Infektionen durch das Immunsystem und/oder UV-
Strahlung reguliert werden können. Wir haben festgestellt, dass im Durchschnitt eine 
virale DNA-Kopie pro 200 bis 1000 Zellen in 88% der latent infizierten Hautstellen 
mehr als 14 Monate nach der Infektion (p.i.) nachgewiesen werden kann. Die 
Kopienzahlen sind dagegen drastisch erhöht, wenn latente Hautproben in Zellkultur 
explantiert wurden. Niedrigdosierte UV-Strahlung allein zeigte keinen signifikanten 
Effekt auf die Viruslatenz. Wir beobachteten eine Zunahme der Virusgenom-
Kopienzahlen in latent infizierten Hautstellen bei Immunsuppression. Obwohl das 
Auftreten von drei Papillomen auf einem Kaninchen im latenten Zustand 
wahrscheinlich durch die Immunsuppression aktiviert wurde, zeigte die Mehrheit der 
latent infizierten Stellen und die anderen Kaninchen keine Papillomneubildung. 
Überraschenderweise zeigte die Kombination von Immunsuppression und UVA/UVB-
Strahlung keinen signifikanten Unterschied im Vergleich zur alleinigen 
Immunsuppression. 
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Wir beobachteten außerdem eine dramatische Zunahme des bereits vorhandenen 
Papillom-Wachstums unter CsA-induzierter Immunsuppression. Diese sehr schnell 
wachsenden Papillome korrelierten allerdings nicht mit der viralen DNA-Kopienzahl 
oder der viralen Genexpression. Die Anzahl der T-Zellen und die Expression T-Zell-
assoziierter Zytokine waren aufgrund der systemischen Immunsuppression 
signifikant verringert. Interessanterweise waren die proinflammatorischen Zytokine 
wie IL-8 und IL-1β in den schnell wachsenden Papillomen signifikant hochreguliert. 
Obwohl bekannt ist, dass CsA die Zellproliferation und die Tumorentstehung 
unabhängig vom Wirtsimmunsystem induzieren kann, wurde es in früheren PV 
Studien weithin als Immunsuppressivum verwendet und die Nebenwirkungen von 
CsA auf die PV-induzierte Tumorentstehung wurden nicht untersucht. Unsere 
Ergebnisse zeigen, dass die Proliferation von Kaninchenzellen durch CsA-
Behandlung erhöht wurde. 
Zusammenfassend haben wir das Outbred-CRPV/Kaninchen-Modell für die 
Untersuchung von latenten Infektionen mit kutanen PVs etabliert. Dies ermöglicht es, 
Faktoren zu kontrollieren, die den latenten Zustand regulieren könnten. 
Wir haben gezeigt, dass die kurzfristige Immunsuppression die latenten Virusgenom-
Kopienzahlen erhöhte, aber nicht zu einer Papillomneubildung bei der Mehrheit der 
latent infizierten Stellen führte. Niedrigdosierte UV-Strahlung allein zeigte keinen 
signifikanten Effekt auf die Viruslatenz. Die Kombination von kurzfristiger 
Immunsuppression und UV-Strahlung zeigte keinen signifikanten Unterschied im 
Vergleich zur Immunsuppression allein. Es ist jedoch möglich, dass die Reaktivierung 
der latenten Virusinfektion eine längerfristige systemische Immunsuppression oder 
mehrere UV-Expositionen erfordert. Darüber hinaus haben wir gezeigt, dass die CsA-
basierte Immunsuppression das bereits vorhandene Papillomwachstum durch die 
Reduktion der Immunüberwachung, der Hochregulierung von 
entzündungshemmenden Zytokinen wie IL8 und IL-1β, sowie die CsA-induzierte 
Tumorgenese fördert. 
Unsere Ergebnisse liefern neue Einblicke in die klinische Behandlung von OTRs, die 
eine CsA-basierte Immunsuppression erhalten und mit einer cuHPV-Infektion 
assoziiert sind. 
V 
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1 INTRODUCTION 
1.1 Papillomavirus (PV) 
PVs comprise a diverse group of viruses that establish infections in the mucous 
membranes and cutaneous epithelia (1). PVs are highly host specific and have been 
discovered in a wide range of vertebrates such as humans, bats, birds and reptile 
species (2, 3). To date, more than 240 distinct PV types in 49 genera have been 
characterized at the nucleotide level (FIG 1.1), of these over 170 belong to Human 
papillomavirus (HPV) types, which are divided into five species: Alpha, Beta, 
Gamma, Mu and Nu (4-6). Mucosotropic human PVs (muHPVs) that belong to the 
Alpha HPV species can be further divided into high-risk types and low-risk types 
according to their potential of causing cancer in humans. At least 13 high-risk 
muHPVs types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) have a high risk 
of causing cancer in humans (7, 8). Low-risk muHPV types, such as HPV 6 and 11 
can cause benign tumors (9, 10). Cutaneous HPVs (cuHPVs) represented by the 
species of Beta, Alpha species 4, Gamma species 1 to 5, Mu and Nu are commonly 
found in the healthy skin of the general population (10-12) and have been found to 
cause skin lesions such as benign skin warts, actinic keratosis (AK), 
keratoacanthomas, and be associated with non-melanoma skin cancer (NMSC) (13-
15). The role of oncogenic muHPVs in the development of cancer is fully recognized. 
However, the role of cuHPVs in skin carcinogenesis has not yet been elucidated.  
PVs are circular dsDNA genomes with sizes close to 8 kb and replicate within the 
nuclei of host cells. Viral genomes contain approximately 8 open reading frames 
(ORFs), which are located on one DNA strand of the viral genome (1). These ORFs 
encode PV early genes (E1, E2, E4, E5, E6 and E7), late genes (L1, L2), as well as a 
non-coding region called the upstream regulatory region (URR). Briefly, the 
regulatory genes E1 and E2 modulate transcription and replication of the viral 
genome, the three oncogenes E5, E6, and E7 modulate the transformation process 
of host cells, and the two structural genes L1 and L2 compose the viral capsid (16, 
17). Although there are many similarities in between the PV genomes organization 
(5), there are differences in term of gene expression patterns. For instance, gamma 
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species 6 HPVs (HPV101, 103 and 108) lack an E6 gene (18, 19), and most cuHPVs 
do not encode E5 protein (20).  
 
PV virions are non-enveloped particles, about 55nm in diameter. Their outer shell 
contains 72 pentamers of the major capsid protein L1 situated at the vertices of a T = 
7 dextro icosahedral lattice (21). The features of papilloma virions are conserved 
despite significant differences in amino acid sequences of L1 (22) (FIG 1.2).  
 
 
 
 
 
FIG 1.1 Papillomavirus phylogenetic tree. The DNA sequence coding for E1, E2, L1 and L2 for all 
241 papillomaviruses were used for construction of the phylogenetic tree. (Adapted from Van 
Doorslaer, et al 2013). 
FIG 1.2 Papilloma virions. CRPV: Cottontail rabbit papillomavirus; BPV: Bos taurus papillomaviruses, 
also known as bovine papillomaviruses; HPV1: Human papillomavirus 1 (Adapted from Trus, et al. 
1997 & Belnap, et al.1997). 
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1.2 The life cycle of PVs 
1.2.1 Attachment, entry, uncoating and intracellular trafficking 
PVs infect the undifferentiated basal cells of the stratified epithelium only when 
wounds or abrasions allow the virus to penetrate the physical barrier of the upper 
skin layers. The infectious entry of PV particles into basal cells occurs via the 
“micropinocytosis” pathway, which requires receptor signaling and actin cytoskeleton 
rearrangement (23). The viral major capsid L1 protein mediates initial binding to 
heparan sulfate proteoglycans (HSPG) within the basement membrane. This binding 
process induces exposure of the hidden amino terminal portion of the viral minor 
capsid L2 protein, which is facilitated by the host cell chaperone cyclophilin B (24-
26). The exposed L2 is subsequently cleaved by a furin convertase. These 
processes result in a loss of affinity to the primary attachment receptor and a transfer 
to an elusive second receptor that probably resides in or is associated with the 
tetraspanin-enriched microdomains (26). However, the complete early process of PV 
remains poorly understood at the molecular level.  
The infectious entry of PVs into basal cells occurs via a clathrin and caveolin 
independent endocytic pathway. The tetraspanin CD151 is essential for PVs 
endocytosis (23). Internalized PV virions initially reside in smooth endocytic vesicles. 
The uncoating of PV virions is triggered by acidification of the endocytic vesicles 
followed by cyclophilin-mediated dissociation of the majority of L1 proteins from the 
viral genome (27). For intracellular trafficking, the viral DNA along with L2 is 
retrogradely transported by the retromer complex and Rab GTPases via microtubules 
to the trans-Golgi network (TGN) (26).  
1.2.2 Viral transcription, replication, transformation and release 
The transcription of PVs is regulated by viral transcription and cellular factors, and 
viral promoters, cellular differential RNA splicing, transcription termination signals etc. 
One of the major regulators of PV’s transcription is the viral early protein E2, which 
activates or represses transcriptional processes, depending on the binding of E2 to 
the context of the E2 binding sites (E2BS) in relation to the early viral promoter 
during viral life cycle (28). One well-known cellular interactor of E2 is the 
Bromodomain-containing protein 4 (Brd4) which recruits cellular transcription factors 
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and chromatin regulators to control transcription (29). The binding of Brd4 to E2 
stabilizes E2, regulates E2-mediated transcription, as well as anchors E2 and viral 
genomes to the host chromosome during mitosis (28, 30). PVs initiate transcription 
via two major viral promoters, the early promoter (PE) and late promoter (PL). The 
regulation of PV’s gene expression is tightly controlled by the differentiation of 
epithelia cells. In the early stage, transcription from viral PE generates mRNAs 
encoding the early genes (E1, E2, E4, E5, E6 and E7), whereas at the late stage, the 
terminal differentiation of the host cells downregulates the activity of PE, resulting in 
the activation of the viral PL to express late genes (L1 and L2) (24). 
The replication of PVs’ genomes is mainly controlled by the interaction of E2 with the 
viral helicase protein E1. E2 forms heteromers with E1 to stimulate initiation of viral 
replication. The binding of viral E1/E2 complex to the viral origin of replication (ori) 
within the URR recruits the cellular DNA polymerase to the episomal viral genome for 
the replication (31, 32). E1 unwinds viral DNA and attracts replication proteins to 
proceed the replication bi-directionally. Initially, the viral genome replicates at low 
levels in the basal cells (33). For viral episomal maintenance during persistent 
infection, PVs control their copy number via E2 and E8^E2 (former name E8^E2C) 
repressor proteins. E2 repressor proteins only retain the carboxy-terminal domain 
that mediates dimerization of E2 proteins and viral DNA recognition. The E8^E2 
protein consists of the small E8 peptide fused to the C terminus of E2, which is an 
important negative regulator during viral life cycle (34).  
As the infected cells differentiate towards the upper layer of the epithelium, the host 
cell downregulates the expression of cellular factors that are essential for viral DNA 
replication (28). This downregulation is counteracted by the viral oncoprotein E7, 
which binds to the tumor suppressor retinoblastoma protein (pRb) releasing E2F 
transcription factors to restore the expression of DNA replication factors in the 
infected cell. Another consequence of a high-level E7 is an induction of the tumor 
suppressor protein p53 (35), which is targeted by most of the alpha HPV E6 for 
proteasomal degradation. In addition, the protein E5 localizes to the membrane of the 
infected cell, where it binds to epidermal growth factor receptor (EGFR) and causes 
receptor dimerization. This results in the transmission of mitogenic signals to the 
nucleus, thus stimulating cell growth (36). With the help of E1 and E2, the 
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oncoproteins E5, E6, and E7 create a suitable environment that promotes efficient 
viral replication. However, it has being shown that the accumulation of E1 proteins in 
the cell nucleus triggers a DNA damage response and causes cell arrest in S-phase 
(33), whereas high levels of E2 can inhibit the early promoter and downregulate the 
expression of the growth-promoting oncoprotein E6 and E7, which lead to the 
differentiation of the infected cell in response to cellular signals (28). Induction of the 
late genes L1 and L2 is delayed until the host cell becomes terminally differentiated 
and E2 no longer represses the promoter PL, resulting in the production of progeny 
virions in the superficial layer of the epithelium. Finally, the viral protein E4, which 
has been shown to cause a collapse of the cellular intermediate filament network, 
might aid the release of virions (37). 
In the past few decades, studies have been mainly focused on the lifecycle of 
muHPVs, especially the high-risk types such as HPV 16 and 18. However, cuHPVs 
have been less studied compared to muHPVs. Most cuHPVs express E6 and E7 
gene products that are structurally similar to those of the muHPVs but their genomes 
do not encode E5 protein (20). The E5 protein plays a role in the productive phase of 
the viral lifecycle and stimulates mitogenic signals of growth factors in most muHPVs 
(36). However, it is yet unclear what the consequences on the lifecycle are for 
cuHPVs lacking E5 (38). In addition, E6 proteins of cuHPVs such as cuHPV 1 and 8 
neither bind to p53 or E6 associated protein (E6-AP) (39). E7 proteins of cuHPVs 
such as type 5 and 8 showed lower binding affiliate to pRb compared to HPV16 E7 
(40). The E6 or E7 protein of cuHPV 1 and 8 showed no true immortalizing activities 
in primary human keratinocytes (41), but E6 and E7 of cuHPV 38 were shown to 
immortalize primary human keratinocytes (42). Instead of directly binding to p53, the 
cuHPV 5, 8, and 38 E6 interact with the histone acetyltransferase p300 and block 
p53-mediated apoptosis, which suggests a role in skin carcinogenesis (43, 44). E6 
protein of cuHPV 5, 8, 20, 22, 38, 76, 92, and 96 has also been shown to degrade 
Bak protein - a pro-apoptotic effector expressed in human epidermal keratinocytes, 
and protect UV-treated keratinocytes from apoptosis in vitro (45). 
1.3 CuHPV and Non-melanoma skin cancer (NMSC)  
CuHPVs induced skin warts are benign, often regress spontaneously. Skin warts 
differ in clinical morphology and histological appearance, which include common 
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warts (cuHPV 2, 4, 7 and 57), deep plantar and palmar, myrmecial warts (cuHPV 1), 
plane warts (cuHPV 3, 10 and 41), intermediate warts (cuHPV 26, 27, 28 and 29) 
and cystic or punctate, mainly plantar warts (cuHPV 60, 63 and 65) (46). 
It has been implicated that some cuHPV infections are associated with the etiology of 
NMSC, other than the well-known factors such as cumulative sun exposure, age, 
gender, fair skin type, and immunosuppression (47). NMSC is more common than 
lung, breast, prostate, and colon cancer combined, and its rate is increasing by 4 - 
8% each year (48). The most common types of NMSC are basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC) which account for approximately 80% 
and 16%of all skin cancers, respectively. SCC and BCC are both derived from the 
basal layer of the epidermis of the skin, but SCCs can be highly invasive and 
metastasize, whereas BCCs are slow growing and rarely metastasize (49).  
1.3.1 Epidermodysplasia Verruciformis (EV) 
The first evidence that cuHPV infection associated with SCC has been found in 
patients with the rare genetically determined condition EVs (50). EV is a heritable 
disease, which is characterized by an abnormal susceptibility to specific types of 
HPV infection, namely EV-HPV (now classified β-HPV) which include HPV types 5, 8, 
9, 12, 14, 15, 17, 19-25, 36, 38 and 47 (15, 51). In early childhood, EV patients have 
a propensity to develop warts and characteristic macular lesions on the face, dorsa of 
the hands, and legs, which usually persist throughout lifetime (15, 52). In 
approximately 30 – 60% of the cases lesions progress to SCC at sun-exposed body 
sites, more than 25 – 30 years after their onset (52, 53). All EV individuals share at 
least 7 mutations in the EVER1 gene and 5 mutations in EVER2 gene, which are 
involved in ion transportation and signal transduction (54-56). A Defect of these two 
genes in EV patients appears to specifically enhance susceptibility to EV-HPV 
infections (55). However, the exact role of the EVER genes in the pathogenesis of 
EV-HPV infection has not been clearly elucidated (38, 55). It is also likely that 
immunogenic and environmental factors, particularly UV light radiation, are important 
for EV-HPV infections in EV individuals, due to partial defects in cell-mediated 
immunity, such as inhibition of natural killer cell activity and of cytotoxic T cells (57, 
58).  
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1.3.2 Organ Transplant Recipients (OTRs)  
SCC is a most common skin cancer in OTRs, occurring 60 to 250 times more 
frequent than in the general population (59). A diverse group of cuHPV DNAs has 
been frequently detected in SCC lesions raising the question of a possible role of the 
viruses in skin carcinogenesis (51, 60, 61). The incidence of cuHPV related warts in 
renal transplant recipients (RTRs) steadily increases over the years post-
transplantation and these lesions are refractory to most therapeutic strategies (59, 
62). RTRs have a 200 fold increased incidence of SCCs, which arise on sun-exposed 
areas (60). The presence of cuHPV DNA in SCCs of OTRs suggests parallels to EV 
patients in terms of the association between HPV infection and skin cancer. 
However, notable differences between these two types of patients include: In OTRs, 
1) multiple cuHPV types can frequently be found in the SCCs of OTRs instead of one 
single predominant type. 2) the viral DNA loads in SCCs are very low, more than five 
log fold lower compared to the warts associated with HPV infection (61, 63). 3) no 
viral transcripts could be found in the SCCs (64, 65). To date, although cuHPV types 
can induce various skin lesions, their role in the pathogenesis of SCCs remains 
controversial. 
1.3.3 UV radiation and cuHPV infection 
Solar UV light is composed of three classes: UVA (320–400 nm), UVB (280–320 
nm), and UVC (200–280 nm). It is well known that UV radiation plays a significant 
etiological role in NMSC development, primarily due to the DNA-damaging properties 
of UVB (66, 67). UVB light has long been implicated as an important risk factor for 
the development of cuHPV associated cutaneous carcinomas in immunosuppressed 
OTRs (68) and in the non-immunosuppressed general population (69), as most 
lesions appear in sun-exposed body sites versus sun-protected sites (13, 68). It has 
been shown by several studies that cuHPV E6 can increase the tolerance of cells to 
UVB radiation via targeting and abrogating Bak function to impair the cellular 
apoptosis signaling to DNA damage response (DDR) (45, 58, 70). Moreover, the 
ataxia-telangiectasia-mutated (ATM) and ataxia telangiectasia and Rad3-related 
(ATR) kinase that is involved in UV-induced DDR is also inhibited by cuHPV 5, 8 E6 
(70, 71).  
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Beyond modulating of the cellular DDR, UVB has also been shown to play a key role 
in inhibiting cell-mediated immune response both in short-term and long-term (72, 
73), and reducing T-cell sub-population in the skin (74). The decreased immune 
surveillance might therefore help to drive PV-induced disease. Recently, Uberoi, et 
al., have shown that UVB-induced immunosuppression increases the susceptibility of 
Mus Musculus papillomavirus 1 (MmuPV1) infection in immunocompetent mice (75). 
1.3.4 Epidermal stem cells (ESC) and cuHPV infection 
The epidermis forms the outer layer of the adult skin, which comprises a multi-
layered epithelium, the interfollicular epidermis (IFE), hair follicles (HFs) and 
sebaceous glands (SGs) (76). ESCs residing in the epidermis and HFs ensure adult 
skin homeostasis, hair regeneration and the repair of the epidermis after injuries (77). 
In the viral life cycle, it is known that PVs establish infections in the basal layer of the 
epidermis. Considering the transit time of cells through the differentiation program of 
the epidermis from the basal layers to being shed, PVs must reside in cells that are 
retained for long periods in the epidermis. Whether PV infects and is maintained in 
ESCs, or confers stem cell-like properties to more differentiated cells, is currently 
unknown (15). Cells in the HF stem compartment were regarded as the primary 
target (78) and the natural reservoir of cutaneous PVs (61). The cuHPV DNA has 
been frequently detected in plucked eyebrow hairs, which contain cells of the HF 
stem cell niche, although the exact target cells of the cuHPV was not determined (79, 
80). It is possible that cuHPV may increase the self-renewal capacity of ESCs, which 
may lead to the generation of cancer stem cells driving NMSC development. A better 
understanding of the effects of cuHPV on ESCs may be beneficial for disease 
management and treatment in the future (15).  
1.4 PV latent infection  
Viral latency is defined as “a reversible state in which the viral genome is present in a 
cell without production of infectious virus particles” (81). Although many viruses are 
capable of asymptomatic infections, only a few are known to undergo truly latent 
infection. To qualify as viral latency, infections must display persistence and 
reactivation. Infection by herpesvirus species such as Herpes simplex virus 1 (HSV-
1; α-herpesvirus), cytomegalovirus (β-herpesvirus), Varicella virus (α-herpesvirus) 
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and Epstein-Barr virus (EBV; γ-herpesvirus) leads to a lifelong latent infection (82). It 
is believed that similar to these latent viruses, PVs can also establish latent infections 
(32, 83, 84).  
At present, the ability of PVs to establish latent infection is still controversial (84). 
Although no direct evidence for a solely latent HPV infection has been found, a 
number of clinical observations and studies in animal models suggest that it may 
occur. 
1.4.1 Clinical evidence for HPV latency  
1.4.1.1 Immunocompromised patient 
Human immunodeficiency virus (HIV) infected patients have a higher incidence of 
cervical HPV infection than HIV-negative patients (85). Studies have shown that 
women with a historic infection of high-risk HPV might be at risk of reactivation of 
viral infection even in the absence of sexual activity, and the risk is higher in 
individuals with HIV infection (86, 87). An increased reactivation of latent cervical 
HPV infection has been shown to be associated with a reduction in peripheral blood 
CD4+ cell counts suggesting that a reduction in cell-mediated immunity is important in 
permitting persistence of such infection (87).  
There is also evidence that OTRs undergoing iatrogenic immunosuppression to 
prevent rejection of transplanted organs are at greater risk for cuHPV infections. In 
general, cuHPV DNAs were detected in plucked eyebrow hairs (68, 88, 89) and on 
clinically normal skin (12, 90, 91), where they predominantly induce asymptomatic 
infections in immunocompetent individuals. However, beta-HPVs have more 
frequently been found predominantly with higher viral loads in immunosuppressed 
OTRs (68, 92, 93).  
1.4.1.2 Recurrent respiratory papillomatosis (RRP) 
RRP, also known as laryngeal papillomatosis, is characterized by exophytic, wart-like 
lesions of the upper airway that tend to recur and have the potential to spread 
throughout the respiratory tract (94). Lesions of this disease are caused by infection 
with low-risk muHPV type 6 or 11. Despite the removal of infected tissues by laser 
treatments, papillomas constantly and rapidly recur. It is thought that recurrent 
lesions are caused by reactivation of HPV infection in a latent state with subsequent 
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spreading of infectious virions (95). This is supported by the frequent detection of 
HPV type 6 or 11 DNA in biopsy samples taken from non-diseased regions of the 
respiratory tract of RRP patients (96, 97).  
1.4.1.3 Recurrent genital papillomas 
Genital warts are the most common venereal disease, which are mainly caused by 
infection with low-risk muHPV type 6 or 11 (98). The infection is considered to have a 
high rate of transmission with lesions arising within two or three months of infection 
that mostly spontaneously regress. Treatments of these lesions include surgery 
cryotherapy, anti-proliferative agents and topical immunomodulatory agents. 
However, recurrence rates of 25% within three months are reported and can be as 
high as 67% despite treatment being given (99). Recurrences of genital warts are 
typically seen at sites of previous infection suggesting that HPV can persist in long-
lived cells at these sites in the absence of clinical signs of disease with subsequent 
reactivation leading to re-emergence of lesions (100). 
1.4.1.4 Latent infection of the cervix 
There is growing evidence from recent studies that some cervical HPV infections 
may be present in a latent state. Most notable is the detection of HPV DNA at low 
copy number in histologically normal cervical epithelial cells (101). Analysis of HPV 
DNA was performed on tissue sections taken from histologically normal tissue 
adjacent to cervical lesions. Highly sensitive laser capture micro-dissection (LCM) 
and real-time PCR techniques were used for analysis. It was found that the 
determined viral DNA copy numbers were indicative of infections of single cells or 
small groups of cells harboring low levels of viral DNA among hundreds of cells 
analyzed. It is possible a representation of latent phase (84, 102). 
1.4.2 Animal models of PV latent infection 
Animal PV models are essential in order to study the pathogenesis of PV infections 
and to develop strategies for treatment and prevention. Animal models have been 
used to study latent PV infection. 
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1.4.2.1 Latency of Rabbit oral papillomavirus (ROPV) 
ROPV is a naturally occurring virus infecting mucosal tissues of domestic rabbits 
(103). Typically, infection of ROPV induces papillomas on the underside of the 
tongue, which regress spontaneously in 100% whitin to 8 weeks p.i. (104). However, 
the immune-mediated regression does not result in completely clearance of viral 
infections. Maglennon et al., (105) have shown that a low copy number of ROPV 
DNAs (1 copy/ 10,000 GAPDH) were still detectable up to 52 weeks p.i.. Using LCM 
they were able to determine that cells harboring persistent viral DNAs were only 
retained in the basal layer of epithelium. In addition, Maglennon et al., (106) have 
further demonstrated that systematic immunosuppression using cyclosporin A (CsA) 
and Dexamethasone (Dex) led to the elevation of viral copy numbers in a minority of 
the infected sites and subsequent formation of only one papilloma. They believed 
that activated T-cells accumulate within and beneath the lesion, which may lead to 
the suppression of latent viral infection, but the balance can be affected by factors 
such as immunosuppression and allow reactivation to occur with the possible 
reappearance of visible papillomas (32, 83). So far no convincing data are available 
on the reappearance upon immunosuppression. 
1.4.2.2 Latency of Cottontail rabbit papillomavirus (CRPV) 
CRPV infection of New Zealand White (NZW) rabbits is the only small animal model 
that enables the study of PV infection and disease, including malignant progression 
(107, 108). This animal model was the first proposed in vivo model system for latent 
PV infection (109, 110). It has been shown that inoculation of domestic rabbit skin 
with a low-titer virus leads to asymptomatic infection. CRPV DNA can be detected at 
the asymptomatic sites 18 weeks post-infection (109). Further irritation of these sites 
with a photosensitizer resulted in subsequent papilloma formation at some sites 
(109). Moreover, irritation of asymptomatic infected sites with UV light during the 
incubation period led to an increase expression of E6 and E7 gene as early as one 
week after irradiation and subsequently papillomas formation at 26% of all irritated 
sites. However, attempts to activate infections that remained latent by repeating UV 
irradiation at the end of the three months observation period were unsuccessful 
(110).  
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In addition, our group earlier analyzed skin tissue from CRPV infected rabbits 
following immune-mediated regression of papillomas (111). We found that viral DNA 
and mRNA encoding early viral proteins were detectable during the regression of 
papillomas by in situ hybridization, but were not detectable using these methods after 
full regression. However, using more sensitive PCR methods, it was possible to 
detect viral DNA as late as 17 months after regression. Analysis of viral DNA copy 
numbers showed that papillomas contained about 7.5 copies per cell whereas 
regressed sites contained one copy per 40 - 1000 cells (111).  
1.4.2.3 Latency of Bovine papillomavirus 2 (BPV2) 
BPV2 induces classical skin warts and was originally isolated from the neck and 
shoulder of a British cattle (112). It has been shown that the virus was also involved 
in bladder cancer in cattle (113). The infection of BPV2 was frequently found latent in 
the healthy skin and in the bladder. Campo et al., (113) has shown that latent BPV2 
could be activated by immunosuppressive treatment -either by feeding bracken fern 
or by azathioprine treatment, as in the bladder and skin(114).  
1.4.2.4 Latency of Mastomys natalensis papillomavirus (MnPV) 
MnPV was first isolated from adult animals of the inbred line “GRA Giessen” of 
Mastomys natalensis that is a common rodent in South Africa (115). MnPV induces 
keratoacanthomas and papillomas of the animal skin, in an age-dependent manner 
(116). Persistent infections of MnPV lead to stomach cancer in 28 – 53% of animals 
older than one year (117). The inbred Mastomys colony (Heidelberg colony) is free 
from malignances, and was found to retain endogenous latent MnPVs (116). Tumors 
never appeared in the inbred animals under one year of age, but 80% of the animals 
developed tumors around 16 months of age (116). Treatment of the latently infected 
skin with TPA, a tumor-promoting molecule drug, dramatically increased latent viral 
DNA copy numbers (100 fold) and tumor formations (118).  
1.4.2.5 Latency of Mus Musculus papillomavirus 1 (MmuPV1) model 
MmuPV1, also designated ‘‘MusPV1’, was first discovered in an inbred colony of 
NMRI-Foxn1nu/Foxn1nu (nude) laboratory mice by Ingle and colleagues (119). The 
infected nude mice spontaneously developed papillomas at the mucocutaneous 
junction of the nose and mouth (119). MmuPV1 virons isolated from papillomas also 
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showed the ability to infect mucosal tropism such as vaginal, cervical and anal (120). 
Most recent studies have shown that the infection of the MmuPV1 is species-specific 
to mouse strains (121). The depletion of CD3+ cells permits the virus efficiently to 
infect non-susceptible immunocompetent mice. However, neither the depletion of 
CD4+ nor CD8+ cells alone increased the susceptibility of MmuPV1 infections (121). 
Remarkably, Wang, et al., (122) showed that despite no appearance of papillomas in 
CD4+ or CD8+ depleted mice upon MmuPV1 infection, the viral DNA can still be 
detected up to 5 weeks p.i.. When anti-CD3 antibody was applied to the mice, 
papillomas significantly appeared only in the CD4+ depleted group (14/15) within ten 
weeks indicating a possible reactivation of latent infection from the asymptomatic 
site, but not in the CD8+ depleted group (1/15).  
1.5 Introduction to CRPV model system 
CRPV, also known as Shope rabbit papillomavirus or Sylvilagus floridanus 
Papillomavirus 1 (SfPV1), was the first PV to be identified in wild cottontail rabbits 
bearing large warts around the head and neck in 1933 (123).  Early investigations 
demonstrated that CRPV could infect laboratory rabbits of various strains, such as 
NZW rabbits, as well as wild snowshoe rabbits and jack rabbits (124). Since then, the 
CRPV NZW rabbit model has been used extensively to study virological aspects of 
PV infections in vivo, virus-induced carcinogenesis, immunological features of virus 
infection leading to host immune-mediated regression, interactions between 
papillomas and cocarcinogens and viral gene function (124-126). One unique 
property of the CRPV model is that infections can be initiated using purified viral DNA 
(127). This property allows for the functional testing of viral mutants in vivo (128), 
which is why this model was widely used to explore the interaction between host and 
virus; and to develop vaccines against PV infections (107, 108, 129).  
1.5.1 Molecular biology of CRPV 
The CRPV genome is 7868 bp in size. It has a similar genome organization, 
expresses in similar differentiation-specific patterns in lesions, and encodes proteins 
with conserved sequence and function as other PVs (130).   
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1.5.1.1 Viral transcriptions 
Like other PVs, the CRPV genome consists of early genes and late genes (FIG 1.3). 
To better reflect the expression pattern in vivo, as well as the organization of the 
CRPV genome, the genome can be divided into early genes (E1, E2, E4, E5, E6, E7, 
and E10) and late genes (L1 and L2). Unlike other PVs, mapping of viral transcripts 
from CRPV-induced tumors strongly suggests that two different E6 transcripts, long 
E6 (LE6) and short E6 (SE6), are produced. LE6 initiates at the first AUG, and SE6 is 
translated from a separate mRNA starting at the second AUG (131).  
In the early stages of the CRPV life cycle, transcription from the early promoters (PE-
1, PE-2, and PE-3) generate mRNAs encoding all early genes, which are 
polyadenylated at the early polyadenylation signal (Poly-AE) (FIG 1.3). These 
polycistronic viral mRNAs are subject to alternative splicing through the differential 
use of various early splice donors (SD) and splice acceptor (SA) sites. As the 
infected epithelial cell differentiates, the late promoter (PL) is activated. Expression 
from the PL bypasses E6 and E7 genes and induces expression of E1, E2C, E8^E2 
(former name E9^E2C) and E1^E4 mRNAs. These mRNAs are also polyadenylated 
at Poly-AE. The E1 and E2 proteins bind to the origin of replication (ori), which is 
located in the URR of the CRPV viral genome. Terminal differentiation of the host cell 
downregulates the activity of Poly-AE resulting in a read-through into the late region 
of the genome, encoding L1 and L2 protein, followed by polyadenylation at late Poly-
A (Poly-AL) to generate L2 and L1 mRNAs (24, 132-134).  
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1.5.1.2 Viral proteins  
The CRPV genome encodes two E6 oncoproteins, LE6 and SE6 (135, 136). The LE6 
protein is 39 kDa and predominantly present in the nucleus in which it appears to be 
associated with the nuclear matrix, with minor portions present in the cytoplasm and 
the membrane fraction. Unlike LE6, the 24 kDa SE6 is a soluble cytoplasmic protein 
phosphorylated at serine residues (135). Both E6 proteins contain Cys-X-X-Cys zinc-
binding motifs and are able to block p53 mediated apoptosis via binding to p300 for 
cellular immortalization and tumorigenesis (43, 132).  
The 14 kDa CRPV E7 oncoprotein is 56% identical to the HPV16 E7 protein and, like 
its human counterpart, can transform established cell lines, bind pRB, disrupt pRB-
E2F complexes (41, 137-139).  
FIG 1.3 CRPV genome and representative mRNAs. A, distribution of the open reading frames on 
CRPV genome. B, each mRNA represents the likeliest candidate mRNA for production of the 
corresponding proteins. (Adapted from Wettstein, et al.,1983, 1987; Nasseri, et al., 1984;  
Georges, et al., 1984; Danos, et al., 1985; Zeltner, et al., 1994) 
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The CRPV E10 gene (former name E8) encodes 51 amino acids and CRPV E5 
genome encodes 101 amino acids (130). Both are able to stimulate rodent fibroblast 
proliferation, promote cell cycle transition, and induce anchorage-independent growth 
and that CRPV E10 and E5 transfected C127 cells were weak tumorigenic in nude 
mice (140). Other studies showed that CRPV E10 provides an essential function in 
papilloma formation and growth, most likely by promoting stem cell proliferation 
(141). However, unlike its human counterpart, the CRPV E5 located downstream 
from poly AE is dispensable for the viral infection in domestic rabbits (142, 143).  
The 68 kDa CRPV E1 protein is an ATP-dependent DNA helicase and is essential for 
viral genome replication and amplification. However, there are still some 
controversies in regarding to whether E1 is required to maintain the viral episomal 
DNA in undifferentiated cells (33). 
The 49 kDa CRPV E2 protein consists of an N-terminal domain and a C-terminal 
domain which is connected by a flexible hinge region. The C-terminal domain of E2 is 
responsible for the binding to the specific sequences - ACCN6GGT located within the 
URR of the viral genomes, whereas the N-terminal domain is involved in viral 
transcription activity (28). The CRPV E2 protein stimulates both viral DNA replication 
and transcription. The transactivation domain in the N-terminal CRPV E2 protein is 
essential for induction of papillomas in NZW rabbits, which functionally depends on 
amino acids isoleucine at position I73 (I73) and arginine at position 37 (R37) (144). In 
addition to CRPV E2, the fusion protein CRPV E8^E2, which is a partial C-terminal 
E2 protein fused to a short stretch of protein derived from the small E8 open reading 
frame was shown to be a repressor of viral promoters (134). CRPV E8^E2 represses 
the E1/E2 dependent replication of the CRPV genome origin and counteracts the 
transactivation effect of the full-length E2 on minimal promoters containing several 
E2BS. However, mutated CRPV E8^E2 within the whole virus genome showed no 
phenotype during tumor induction in NZW rabbit models (134). 
The CRPV E4 protein is produced in the late stage of the viral life cycle. It was shown 
not to be required for papilloma development and extrachromosomal viral DNA 
status. The expression and the amplification of the E4 protein correlated with the 
expression of the L1 protein and were detected in the more differentiated epithelium 
layers (37, 145). 
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1.5.1.3 State of CRPV DNA 
The rabbit papillomas, primary carcinomas, and metastatic carcinomas caused by 
CRPV in domestic rabbits contain 10 to about 100 copies of the CRPV viral genome 
per diploid cell equivalent of DNA. In its natural host cottontail rabbits, the viral gene 
copy number of papillomas is higher, ranging from 1,000 to 10,000 copies (146). The 
average number of viral gene copies per neoplastic cell decreases dramatically to 
less than 100 copies per cell as cottontail papilloma progress to carcinoma (147). In 
papillomas, most viral DNA is maintained as nicked or supercoiled episome DNA 
(147-149). The situation can be different in carcinomas. Most of the viral DNA was 
maintained in form of extrachromosomal multiple head-to-tail DNA, and a minority of 
tumors contained a fraction of integrated viral DNA (149). Thus, the transplantable 
VX2 and VX7 carcinomas of domestic rabbits were found to contain only integrated 
DNA with 10 - 40 or 100 - 400 CRPV copies per cell (150).   
CRPV DNA methylation between rabbit papillomas and carcinomas is different. In 
cottontail rabbit papillomas, CRPV DNA was not methylated and the degree of 
methylation increased from domestic rabbit papillomas to carcinomas and was very 
high in the transplantable VX2 carcinoma (126, 151). The most methylated genes 
were located in the late region and E2 of the CRPV genome (126).  
1.5.2 Immune response and regression 
Neutralizing antibodies had been found to recognize both capsid proteins, CRPV L1 
and L2 (152, 153). Antibody response to the L1 protein was detected in essentially all 
rabbits with papillomas 4 to 6 months after infection. An antibody response to the L2 
minor protein was detected only in some rabbits. A limited immune response to the 
early protein E1, E2, E6, and E7 was only detected in a fraction of the animals, and 
no specific response was found for E4 and E5 protein (152, 154). The response to 
E6 and E7 peaked around 7 months and decreased thereafter. In contrast, that to E1 
and E2 remained high after an initial raise. A much higher response to the E2 protein 
was observed in regressor rabbits (111, 154).  
Spontaneous regression of PV-induced papillomas in humans and cottontail rabbits 
is relatively common. However, the regression of CRPV induced papillomas in 
domestic rabbits is rare. If it happens, most regressions occur within 30 to 60 days 
post infection, but some begin as late as 90 days. Once initiated, the regression 
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proceeds at a steady pace and is complete within 1 - 2 weeks. However, when 
papillomas reach a certain size, there is a much lower chance for spontaneous 
regressions to occur (155). It has been shown that the papilloma regression process 
was associated with infiltration of leucocytes (156), most notably of CD8+ cells (111); 
and an immune response to the CRPV E2 protein (154).  
During regression, expression of the early genes E6 and E7 remains at levels 
comparable to those in persisting papillomas. After complete regression, viral 
transcripts are no longer detectable, but surprisingly regression does not result in the 
elimination of all cells which harbor viral DNA. The viral DNA was maintained 
extrachromosomally in the cells after regression and persisted in on case in a latent 
stage for prolonged periods for 17 months (111).   
In a former study, Hu et al (157) have shown that administration of the 
immunosuppression drug CsA could prevent the regression of cutaneous papillomas 
induced by CRPV. They also demonstrated the ability of CsA to cause a reduction in 
CD4+ and CD8+ stained peripheral blood leukocytes.  
1.6 Study objectives 
In summary, cuHPV infections are highly prevalent and tend to persist in the skin of 
the general population (11, 90, 91, 158). The presence of beta-HPV infections has 
been suspected to be involved in the development of NMSC, besides well-known risk 
factors, such as immunosuppression and UV radiation (38, 63, 93, 159). The ability 
of PVs to persist in their host in the absence of causing overt disease, i.e latency, 
has long been suspected (83). Several lines of clinical evidence support the 
hypothesis that PVs can establish latent infections such as HIV individuals with high 
rate of multiple infections to specific types of HPVs; and OTRs with a high prevalence 
of cuHPV associated infections especially in sun-exposed body sites. In addition, 
drug-induced immunosuppression and UV light radiation have been implicated as 
contributing factors for the reactivation of latent PVs infections. In animal model 
systems, systematic immunosuppression has been shown to play a role in PVs latent 
infection caused by ROPV, BPV2 or MmuPV1 (106, 122). UV radiation may also 
contribute to PVs latent infection as shown in the CRPV animal model (109, 110). 
Cutaneous infection of NZW rabbits with CRPV represents a tractable animal model 
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that enables in vivo investigation of cuHPV infection. The objective of this study was 
to employ the CRPV/rabbit model to investigate whether the latent cuHPVs infection 
is controlled by the immune system and/or UV-mediated radiation.  
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Animals and viral DNA 
Animals: Three weeks old out-bred female New Zealand White (NZW) rabbits were 
purchased from Charles River, Kisslegg, Germany. 
Viral DNA: The recombinant CRPV genome pLAII-CRPV was used in this project. 
The 7.8 kb CRPV genome has been inserted into the SalI site of pLAII vector 
resulting 11.3 kb pLAII-CRPV. This construct has been shown to induce papillomas 
on NZW rabbits (107, 160). 
2.1.2 Equipment 
Application Name Supplier Location 
Real-time PCR LightCycler® 480 system 
Roche Applied 
Science 
Penzberg, 
Germany 
Gene-Gun 
Helios Gene Gun  
BIO-RAD 
Munich,  
Germany 
Tubing Prep Station  
Tubing Cutter  
Tefzel® tube  
Sonification  
SONOPLUS  Bandelin electronic  
Berlin,  
Germany 
Sonifier® S-250A Branson  
Dietzenbach, 
Germany 
PCR-Machine PTC-0200 DNA Engine Cycler BIO-RAD 
Munich,  
Germany 
Electrophoresis  
chamber 
Mini-Sub Cell GT  
BIO-RAD 
Munich,  
Germany Wide Mini-Sub GT 
Power Supply PowerPac 200  BIO-RAD 
Munich,  
Germany 
Camera system Gel Doc 2000  BIO-RAD 
Munich,  
Germany 
Incubator 
CO2 Incubator US AutoFlow 
(Nuaire) 
NuAire, Inc MN, USA 
Kelvitron T (Heraeus) 
Thermo Fisher 
Scientific 
MA, USA 
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CO2 Incubator C200 Labotect 
Goettingen, 
Germany 
Microscope 
Axiovert 200 Inverted Microscopes Carl Zeiss 
Goettingen, 
Germany 
Leica DMIRB Leica 
Bensheim, 
Germany 
Centrifuges 
Centrifuge 5810R / 5804R  
Eppendorf 
Hamburg, 
Germany 
Centrifuge 5417R / 5417C  
Thermomixer 5436 
Shaker Certomat® IS B. Braun Biotech 
Goettingen, 
Germany 
Vortexer 
REAXtop Heidolph 
Instruments 
Schwabach 
Germany MR3001K 
Spectro- 
photometer 
BioPhotometer  Eppendorf 
Hamburg, 
Germany 
NanoDrop -1000 
Spectrophotometer 
Thermo Fisher 
Scientific 
MA, USA 
Tissue  
homogenization 
T 18 digital ULTRA-TURRAX®  IKA 
Leiden,  
Netherlands 
UVB lamp Vilber Lourmat lamps 
VILBER LOURMAT 
Eberhardzell, 
Germany UVA lamp Vilber Lourmat lamps  
UVX radiometer Ultra-Violet Products, LLC  
Ultra-Violet 
Products Ltd 
CA, USA 
ELISA reader Cytation 3 Imaging Reader 
BioTek® 
Instruments 
VT, USA 
Flow Cytometry FACSCalibur  Becton Dickinson 
Heidelberg, 
Germany 
2.1.3 Accessories 
Disposable culture dishes were purchased from Eppendorf, Falcon, Greiner and 
Nunc. 
Accessories Name # Catalog Supplier Location 
Real-time PCR plate 
LightCycler® 480 Multiwell 
Plate 96, white 
04729692001 
Roche 
Penzberg, 
Germany 
LightCycler® 480 sealing foil  04729757001 
Gold particle 
Biolistic 1.0 µm Gold 
Microcarriers  
1652263 RIO-RAD 
Munich,  
Germany 
Sandpaper P030 180 8633000 Wolfcraft  
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Sterile filter 
0.22 μm  Pro04064 
Millipore 
Billerica, 
UK 0.45 µm Pro04065 
Cell Counter Countess C10227 Invitrogen CA, USA 
2.1.4 Chemicals 
Chemicals were purchased from the following companies: BioRad, Biozym, 
Calbiochem, Fluka, Merck, Peqlab, Perkin-Elmer, Roche, Roth, and Sigma. 
2.1.5 Medical drugs 
Drug Trade name Supplier Class of drug 
Species, dose, 
and route 
Ketamine 
KETAMIN10% 
100 mg/mL 
Bela-Pharm, 
Vechta, Germany 
Dissociative  
anesthetic 
Rabbit: 10 – 25 
mg/kg, s/c or im 
Sedative 
Sedator®  
1 mg/mL 
Eurovet Animal 
Health B.V. Bladel, 
Netherlands 
Sedatives hypnotics 
Rabbit: 0.05 – 
0.1 mg/kg, s/c 
or im 
Dexamethasone 
Dexadreson® 
sodium,  
2 mg/mL 
Intervet Millsboro 
Germany 
Steroid medication 
Rabbit: 0.15 – 
0.25 mg/kg, s/c 
Cyclosporine A 
Sandimmun® 
50 mg/mL 
Novartis Pharma  
Basel, Switzerland 
Immunosuppressant 
medication 
Rabbit: 7.5 – 15 
mg/kg, s/c 
Note: s/c, subcutaneous; im: intramuscular 
2.1.6 Commercial kits 
Application  Kit # Catalog  Supplier Location 
Plasmid 
purification 
EndoFree Plasmid Maxi Kit  12362 
Qiagen 
 
Hilden, 
Germany 
Plasmid Mini Kit 27106 
DNA extraction QIAamp DNA Mini Kit 51306  
Gel Extraction Kit QIAquick Gel Extraction Kit  28706 
RNA extraction RNeasy Mini Kit  74106 
cDNA Synthesis   
QuantiTect Reverse 
Transcription Kit  
205313 
Gene cloning 
Rapid DNA Ligation Kit K1422 Thermo Fisher 
Scientific 
MA, USA 
CloneJET PCR Cloning Kit K123 
Real-time PCR 
LightCycler® 480 SYBR 
Green I Master Mix 
048873520
01 
Roche  
Penzberg, 
Germany 
PrimeTime® Gene Expression 
Master Mix 
1055772 
Integrated DNA 
Technologies 
Leuven, 
Belgium 
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Normal PCR GoTaq® Green Master Mix  9PIM712 Promega WI, USA 
Transfection 
FuGENE HD Transfection 
Reagent 
E2311 Roche 
Penzberg, 
Germany 
Rolling circle 
amplification 
Illustra empliPhi100 
Amplification Kit  
25640010 GE Healthcare 
Milan, 
Italy 
DNA methylation EZ DNA Methylation™ Kit  D5001 Zymo Research 
Freiburg, 
Germany 
Cell proliferation 
Cell Proliferation Reagent 
WST-1 
116448070
01 
Roche 
Penzberg, 
Germany 
2.1.7 Enzymes 
Application  Kit # Catalog  Supplier Location 
Polymerases PyrobestTM DNA- polymerase  TBR005A 
Takara 
Bio Inc. 
Shiga, Japan 
Restriction 
enzymes 
SmaI R0141S New 
England 
Biolabs,  
MA, USA DpnI R0176S 
PspGI R0611S 
2.1.8 Antibodies 
Primary antibodies 
Antibody Clone Species Dilution Conjugation #Catalog 
Supplier 
/location 
T-
lymphocytes 
KEN-5 Mouse 1:20 FITC MCA800F 
AbD Serotec 
/Puchheim, 
Germany 
Rabbit CD4 KEN-4 Mouse 1:20 FITC MCA799F 
Rabbit CD8 C7 Mouse 1:20 FITC MCA1576F 
IgG1 N/A Mouse 1:20 FITC MCA928F 
IgG2a N/A Mouse 1:20 FITC MCA929F 
Cytokeratin 
15 
LHK15 Mouse 1:50 No  sc-47697 
Santa Cruz 
Biotechnology, 
Inc. /CA, USA 
Note: N/A, not available. 
Secondary antibodies 
Antibody  Species Conjugation Dilution #Catalog Supplier /location 
Anit-Mouse 
(green)  
Goat anti-
Mouse,  
IRDye® 800. 
Odyssey 
Infrared Imaging  
1:15000 925-32210 LI-COR® /NE, USA 
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2.1.9 Oligonucleotides 
Name 
Primer/ 
probe 
Sequences (5′ - 3′) Position 
Target 
size 
References 
CRPV E6 
Forward 
CATGCGTTGTACAGTTT
GCG 
444-463 
149 bp 
Designed in 
this study 
Reverse 
TCACCTTGGTCTGACA
GTTTG 
573-593 
TaqMan 
probe 
AAGAACTGCAATGACC
CCTCCACT 
548-571 
GAPDH  
Forward 
GGATTTGGCCGCATTG
G 
N/A N/A 
Maglennon, 
et al. (105) 
Reverse 
CAACATCCACTTTGCCA
GAGTTAA 
TaqMan 
probe 
CGCCTGGTCACCAGGG
CTGC 
CRPV E1^E4 
Forward 
GTGCCCGGAGTGTTGT
AA 
1338-1355 
71 bp 
Culp, et al. 
(161) 
Reverse 
GGTGTCTTCAGGGGCA
CT 
3733-3750 
TaqMan 
probe 
TGAAAATGGCTGAAGC
TCCCC 
1357-1370 ^ 
3713-3719 
CRPV E1 full 
length 
Forward 
ATGGCTGAAGGTACAG
ACCCT 
1362-1382 
1809 bp 
Designed in 
this study 
Reverse 
TCATAGAGACTGAGAA
GTTCC 
3150-3170 
CRPV E2 full 
length 
Forward 
ATGGAGGCTCTCAGCC
AGCGCTTA 
3112-3135 
1173 bp 
Designed in 
this study 
Reverse 
CTAAAGCCCATAAAAAT
TCC 
4265-4284 
CRPV 
SE6/LE6 
Forward 
CTGCAGAGACTGCACT
GTATTG 
3330-251 
137 bp 
Designed in 
this study 
Reverse 
CTTCCGCAAACTGTACA
ACG 
448-467 
GAPDH RNA 
Forward 
GGGTGGTGGACCTCAT
GGT 
N/A 58 bp 
Seol, et al. 
(162) 
Reverse 
CGGTGGTTTGAGGGCT
CTTA 
Bisulfite  
Methprimer 1 
Forward 
TTAAAGTGGTTTGTAAA
GAATTGGTATAAAAAG 
N/A 
306 bp 
Designed in 
this study 
Inner 
reverse 
CTACCTACRATCAAACT
CAATACCAACC 
Outer 
reverse 
CAACCATCATTAAATCA
AAATACATAACACC 
576 bp 
Bisulfite  
Methprimer 2 
Forward 
GTATTYGGTGGTATGT
GATGATATATTATATAG
N/A 397 bp 
Designed in 
this study 
MATERIALS AND METHODS 
25 
TAAG 
Inner 
reverse 
AAGYGTTTTTATTAATTT
TGGGGTATTTTTAAG 
Outer 
reverse 
ATCTCAAATACACAATA
CCAACAACC 
513 bp 
Bisulfite  
Methprimer 3 
Forward 
GATATYGGTTGTTGGTA
TTGTATATTTGAG 
N/A 
254 bp 
Designed in 
this study 
Inner 
reverse 
ACCCCRTACATTTAAAC
AATTATTTTTCTAC 
Outer 
reverse 
CCCCAAATCACCTTAAT
CTAACAATTTACAAAAA
CTAC 
562 bp 
IFN-γ 
Forward 
TTCTTCAGCCTCACTCT
CTCC 
N/A 224 bp 
Godornes, et 
al. (163) 
Reverse 
TGTTGTCACTCTCCTCT
TTCC 
TNF-α 
Forward 
GTCTTCCTCTCTCACGC
ACC 
N/A 335 bp 
Reverse 
TGGGCTAGAGGCTTGT
CACT 
IL-10 
Forward 
GAGAACCACAGTCCAG
CCAT 
N/A 179 bp 
Reverse 
CATGGCTTTGTAGACG
CCTT 
Fas-ligand 
Forward 
ACACCTATGGAATTGC
CCTGG 
N/A 312 bp 
Dewals, et 
al.(164) 
Reverse 
TGACCAGTGATATCTCA
GAGAC 
Perforin-1 
Forward 
CAGTACAGCTTCAACA
CGGAC 
N/A 176 bp 
Reverse 
ATGAAGTGGGTGCCAT
AGTTG 
IL-6 
Forward 
CTACCGCTTTCCCCACT
TCAG 
Exon 2 from ,5; 
NCBI ID: 
NM_001082064  
135 bp 
Schnupf, et 
al. (165) 
Reverse 
TCCTCAGCTCCTTGATG
GTCTC 
IL-8 
Forward 
CCACACCTTTCCATCCC
AAAT 
Exon 2 and 3 
from 4; NCBI ID: 
NM_001082293 
122 bp 
Reverse 
CTTCTGCACCCACTTTT
CCTTG 
IL-17A 
Forward 
CCAGCAAGAGATCCTG
GTCCTA 
Exon 3 from 3; 
NCBI ID: 
XM_002714498 
112 bp 
Reverse 
ATGGATGATGGGGGTT
ACACAG 
IL-1β Forward TTGAAGAAGAACCCGT Exon 3/4 and 4 128 bp 
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CCTCTG from 
,6; NCBI ID: 
NM_001082201 Reverse 
CTCATACGTGCCAGAC
AACACC 
TGF-β 
Forward 
CAGTGGAAAGACCCCA
CATCTC 
Exon 6 and 7 
from ,8;  
NCBI ID: 
NM_001082660 
140 bp 
Reverse 
GACGCAGGCAGCAATT
ATCC 
CCL-4 
Forward 
GAGACCACCAGCCTCT
GCTC 
Exon 2 and 3 
from 3;  
NCBI ID: 
NM_001082196 
123 bp 
Reverse 
TCAGTTCAGTTCCAAGT
CATCCAC 
Note: N/A, not available. 
2.1.10 Bacterial strains 
E. coli DH5α (Catalog #9057, Takara Bio Inc. Shiga, Japan): An endonuclease and 
recombinase-deficient Escherichia coli strain were used for DNA amplification.  
SCS110 Competent Cells (Catalog #200247, Stratagene, CA, USA): SCS110 is 
derived from the JM110 strain, which is ideal for preparing plasmid-free of Dam or 
Dcm methylation. 
2.1.11 Eukaryotic cell lines 
AVS cell line: A cell line derived from CRPV particles transformed New Zealand 
White rabbit keratinocytes. The cell line was designated AVS (Asian Virus Stock). 
Vx2 cell line (Catalog #90030912, supplied by European Collection of Authenticated 
Cell Cultures): Derived from a rabbit Oryctolagus cuniculus tumor of unspecified 
tissue origin, which was caused by a CRPV infection. The CRPV DNA was found in 
head-to-tail tandem integrated repeats within the host cell genome (150). 
2.1.12 Cell culture Medium  
Keratinocyte-SFM (KSFM): Catalog #10744-019, Gibco-BRL, Thermo Fisher 
Scientific, MA, USA. 
Epidermal Growth Factor (EGF) and Bovine Pituitary Extract (BPE): Catalog #37000-
015, Thermo Fisher Scientific, MA, USA. 
2.1.13 Reagents and solution buffers 
10× PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4 . 
MATERIALS AND METHODS 
27 
1× PBS-T: 1× PBS + 0.1% Tween-20. 
10× TBS: 50 mM Tris, 150 mM NaCl, pH 7.6. 
1× TBS-T: 1× TBS + 0.1% Tween-20. 
FACS buffer: 1× PBS with 2% fetal calf serum (FCS). 
Ammonium-Chloride-Potassium (ACK) buffer: NH4Cl (ammonium chloride) 8.02 g; 
NaHCO3 (sodium bicarbonate) 0.84 g; EDTA (disodium) 0.37 g; adjust to 100 mL 
with Millipore water, stored at 4°C for six months. 
LB-medium (Luria-Bertani-medium): 25 g LB Broth Base (GibcoBRL) were solved in 
1 L H2O.  
LB-Agar: 15 g/L select agar (GibcoBRL) in LB medium. 
SOC-Medium: 2% (w/v) Bactotrypton, 0.5% (w/v) Bacto yeast Extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM Glucose. 
2.1.14 Software 
GraphPad Prism 5 (La Jolla, CA, USA); Vector NIT® software (Thermo Fisher 
Scientific, MA, USA); Edit seq (DNASTAR. Inc. WI USA); Gen5TM software (BioTek® 
Instruments, Inc, VT, USA); ZEN 2 software (Carl Zeiss Microscopy GmbH, 
Göttingen, Germany); CellQuest Pro software (Becton Dickinson, Heidelberg, 
Germany). 
2.2 Methods 
2.2.1 Molecular biology methods 
2.2.1.1 General cloning 
The restriction enzyme digestion was typically performed in a volume of 20 µL 
containing up to 1 µg DNA fragments with 1 µL of each unit of enzyme. Reactions 
were incubated at appropriate temperature overnight followed by 15 min at 65°C to 
inactivate the enzyme activity. The ligation of DNA fragments was performed using 
the Rapid DNA Ligation Kit according to the manufacturer’s instructions. The ligation 
mixture was then used directly for bacteria transformation. 
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2.2.1.2 Transformation and propagation 
E. coli DH5α competent cells were used for the propagation of plasmids. 100 µL 
competent bacteria were thawed on ice, mixed with 15 µL ligation mixture and 
incubated on ice for 30 min. Then the mixture was heat-shocked for 90 s at 42°C and 
immediately cooled on ice for 1 min. Finally, 350 µL of SOC-Medium were added and 
incubated for 45 min at 37°C shaking at 700 rpm. The transformation mixture was 
plated on agar plates containing ampicillin and was left to incubate in a 37°C 
incubator overnight. The resulting colonies were then transferred to 5 mL LB liquid 
medium supplemented with 100 µg /mL Ampicillin and were cultured overnight at 
37°C shaking at 220 rpm. For a large scale plasmid preparation, 500 µL bacterial 
preparations were taken from the 5 mL LB culture and were used to inoculate 1 L LB 
broth containing 100 µg/mL Ampicillin, and were left to grow overnight at 37°C, 
shaking at 220 rpm. For making bacterial stock, 1.5 mL of bacterial suspension was 
mixed with 50% of glycerol and frozen at - 80°C. 
2.2.1.3 Mini prep and Maxi prep 
The QIAprep spin mini-prep Kit was used for preparing a small amount of plasmid 
DNAs according to the manufacturer’s instructions. The EndoFree® Plasmid Maxi Kit 
was used for the large quantity of plasmid DNAs preparation according to the 
manufacturer’s instructions.  
2.2.2 DNA methods 
2.2.2.1 DNA extraction and purification 
Total DNA was extracted using the QIAamp DNA Mini Kit according to the 
manufacturer’s instructions. Briefly, proteinase K digestion of the tissue samples was 
performed with lysis buffer overnight at 700 rpm at 56°C. The extracted DNAs were 
used for further detection or stored at - 20°C. The concentration and purity of the 
extracted DNAs were examined using the NanoDrop spectrophotometer. A ratio of 
absorbance at 260 nm and 280 nm was used to ensure the purity of DNA with a ratio 
close to 1.8 indicative of pure DNA. DNA concentrations were calculated by 
measuring absorption at 260 nm. 
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2.2.2.2 Normal PCR 
Oligonucleotide primers for normal PCR were designed using online resources 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The primers with the highest scores 
were selected for commercial synthesis by the Life technologies™ company, 
Germany. For diagnoses, the GoTaq® polymerase and Green Master Mix was used 
for the PCR reaction according to the manufacturer’s instructions. For gene cloning, 
the PyrobestTM DNA-Polymerase was used for the PCR reaction due to its high 
accuracy during DNA replication. The PCR reactions were 50 µL in total volume, 
which composed of 2 µL of 10 mM dNTPs, 5 µL of 10× reaction buffers, 0.25 µL of 
Pyrobest TM DNA-Polymerase, 2 µL of primer sets, 2 µL of the template, and 36.75 µL 
ddH2O. The PCR program was 94°C for 3 min, following 35 cycles of reactions: 
denaturing at 94°C for 30s; annealing at 56°C for 30 min; extension at 72°C for 30 s 
to 90 s. The extension time and annealing temperature varied according to the PCR 
product size and GC content, allowing 60 s of extension per 1000 bp product length. 
The PCR products were examined by 0.8 - 1.5% of agarose gel electrophoresis. 
Purification of PCR products was performed using QIAquick Gel Extraction Kit 
according to the manufacturer’s instructions. 
2.2.2.3 Real-time quantitative PCR (RT-qPCR) 
SYBR Green I based RT-qPCR reactions were carried out using 20 μL reaction 
mixtures consisting of 10 μL of LightCycler 480 SYBR Green I Master, 50 ng of 
template, and 30 pmol of each forward and reverse primers. TaqMan probe based 
reactions were carried out using 20 μL reaction mixtures consisting of 10 μL 
PrimeTime® Gene Expression Master Mix, 1 μL of 20 mM primers and probes mix 
(Integrated DNA Technologies), and 50 ng of cDNA. All primers used in this study 
are listed in section 2.1.9. All RT-qPCR assays were performed using the LightCycler 
480 instrument. Typically amplification for SYBR Green was performed using the 
following program: pre-incubation 95°C for 5 s following 45 cycles of amplification 
95°C for 10 s, 56°C for 10 s, and 72°C for 5 s. The extension time and annealing 
temperature vary in terms of the PCR product size and GC content. At the end of the 
PCR run, a dissociation curve was generated. The melting curve program was 
performed: 95°C for 5 s, 65°C for 1 min, 40°C cooling for 10 s. The viral copy number 
was determined by a standard curve, which was generated by 10 fold dilutions of 
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standard plasmids containing the respective target sequence. The copy number of 
each standard concentration was calculated by the following equation:  
  
2.2.2.4 Rolling circle amplification (RCA)  
RCAs were performed using the Illustra empliPhi100 Amplification Kit following the 
manufacturer’s instructions with 5 mM extra dNTPs and 30 pmol CRPV E6, E2 
primer pairs respectively. Digestions of the amplification products were performed 
using SmaI overnight at 25°C in a total volume of 20 μL. Digestion results were 
verified by 0.4% agarose gel electrophoresis (100 V, 1 h). 
2.2.2.5 Bisulfite-based cytosine methylation analysis  
Total DNA was extracted with the QIAamp DNA Mini Kit and was prepared for 
bisulfite conversion using EZ DNA Methylation™ Kit according to manufacturer’s 
instructions. Bisulfite-treated DNA was amplified by nested PCR with reaction 
conditions as previously described (166) and adapted as follows: Denaturation (95°C 
4 min), cycle 5 (95°C  45 s, 56°C 90 s, 72°C 4 min), cycle 35 (95°C 45 s, 60°C 90 s, 
72°C 90 s), 72°C 4 min, hold 4°C. Methylation-specific primers for bisulfite PCR 
amplification were designed using the online resource from Zymo-research 
(http://www.zymoresearch.de/tools/bisulfite-primer-seeker) and were listed in section 
2.1.9. PCR amplicons were then purified and cloned using CloneJET PCR Cloning 
Kit according to manufacturer’s instructions, and at least 10 positive clones from 
each sample were sequenced. Only sequences with at least 90% conversion of 
cytosines outside CpGs were taken into account.  
2.2.2.6 DNA sequencing 
Sanger sequencing was carried out by GATC biotech AG, Constance, Germany. 
Sequences were analyzed using the Vector NIT® software.  
2.2.3 RNA methods 
To extract RNA, precautions were taken at all times to avoid the potential of RNA 
degradation by the ubiquitous presence of ribonuclease enzymes in cells, tissues or 
the environment. RNA was extracted using the RNeasy Miniprep Kit according to the 
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manufacturer’s instructions. Briefly, for tissue RNA extraction, skin biopsies were cut 
into small pieces (approximately 10 - 40 mg) and were homogenized using the Ultra-
Turrax T18. The homogenized lysates were centrifuged at 14,000 rpm for 10 min and 
subjected to the protocol for “RNA extraction from tissue” within the RNeasy Miniprep 
kit. The extracted RNA was quantified using the Nanodrop and stored at - 80°C. 
Complementary strand DNA synthesis was performed using the QuantiTect® 
Reverse Transcription Kit according to manufacturer’s instructions.  
Gene expression was quantified by RT-qPCR, see section 2.2.2.3. For relative 
quantification, target gene expression was normalized to the expression of the rabbit 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. The 2-ΔΔcp method was 
used for analyzing the results. SYBR Green I based RT-qPCR was performed using 
the following program: 95°C for 5 s following 40 cycles of amplification 95°C for 10 s, 
60°C for 30 s. At the end of the PCR run, a dissociation curve was generated. The 
melting curve program was performed: 95°C for 5 s, 65°C for 1 min, 40°C cooling for 
10 s. For quantitating quantification, a serial diluted standard plasmid containing 
target gene sequence was used. Taq-Man probe based RT-qPCRs were performed 
using the following program: 95°C for 5 s following 40 cycles of amplification 95°C for 
10 s, 60°C for 30 s. All primers and probes were listed in the section 2.1.9. 
2.2.4 In vitro cell culture methods 
2.2.4.1 Normal cell line culture 
Rabbit derived cell lines AVS, Vx2 were cultured in keratinocyte-SFM supplemented 
with human recombinant Epidermal Growth Factor and Bovine Pituitary Extract, and 
1× antibiotics/antimycotics (1000 U per mL penicillin, 1 mg per mL streptomycin). At 
confluency, cells were subcultured by trypsinization and 3×104 cells per cm2 were 
seeded in fresh collagen I coated or Primaria plates.  
2.2.4.2 Ex vivo primary cell culture 
Primary keratinocytes from NZW rabbits were isolated from rabbit skin biopsies using 
a modified protocol as previously described (167, 168). Rabbit skin punch biopsies 
were removed and incubated in a defined DMEM with 5 U per mL dispase II (10 mg 
per mL) and 10× antibiotics/antimycotics (1000 U per mL penicillin, 1 mg per mL 
streptomycin) at 4°C. The skin was then cut into pieces and trypsinized (0.25%/0.1% 
MATERIALS AND METHODS 
32 
trypsin-EDTA) for 20 min. Cells were filtered using 100 µm filter and seeded at a 
density of 3× 104 cells per cm2 in each 6 cm collagen coated plate. The cells were 
cultured in keratinocyte-SFM, supplemented with human recombinant Epidermal 
Growth Factor (EGF) and Bovine Pituitary Extract (BPE), and 1× 
antibiotics/antimycotics. At confluency, cells were subcultured by trypsinization and 
3×104 cells per cm2 were seeded in fresh collagen I coated plates. 
2.2.4.3 Transfection of Eukaryotic cell  
The FuGENE® HD Transfection Reagent was used for eukaryotic cell transfection. 
The ratio of FuGENE transfection reagent to DNA was 5:2. The adherent cells were 
plated one day before transfection so that cells are approximately 80% confluent on 
the day of transfection. In general, 1 - 2×104 adherent cells were plated in 2 mL per 
well of a 6-well plate. The FuGENE® HD Transfection reagent/DNA mixture was 
incubated for 15 minutes at room temperature. The mixture was then added to the 6-
well plate and mixed by pipetting. The cells plate was returned to the incubator for 48 
hours.  
2.2.4.4 Cell proliferation WST-1 assay 
The quantification of cell proliferation and cytotoxicity was determined by WST-1 
based assay according to institutional guidelines. Briefly, cells were seeded at a 
concentration of 5× 103 cells/well in 100 µL KSFM culture medium with EGF and BPE 
in 96 wells Primaria plate. Cells were incubated for 24 h at 37°C and 5% CO2, and 
the culture medium was replaced by KSFM medium with different concentrations of 
immunosuppressant drugs. Cells were incubated for 4 to 5 days at 37°C and 5% 
CO2. And 10 µL/well Cell Proliferation Reagent WST-1 was added and incubated for 
4 h at 37°C and 5% CO2. After thoroughly shaking for 1 min on a shaker, the 
absorbance of the samples against a background controls as blank was measured 
using a microplate (ELISA) reader. The wavelength for measuring the absorbance of 
the formazan product was 440 nm. The reference wavelength was 600 nm. The 
results were analyzed by Gen5TM software.  
2.2.4.5 Immunofluorescence staining 
The primarily expanded rabbit keratinocytes were seeded in 24-well collagen I coated 
plates and were cultured for 2 days in KSFM medium. Cells were fixed with acetone 
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for 5 min at room temperature and were washed in 1× PBS three times for 5 min. 
After incubation with 1% BSA in 1× PBST for 30 min to block unspecific binding of 
the antibodies, cells were incubated with the primary cytokeratin 15 antibody (1:50)  
for 1 h at room temperature. After three times wash in 1× PBS, cellular DNA was 
stained with DAPI for 1 min. Images were obtained with a Zeiss Axiovert 200 
microscope. 
2.3 Animal experiments 
2.3.1 Ethical approval and project license application 
All animal experimental procedures were approved (Permit Number: H2/13) by the 
responsible authority (Regierungspraesidium Tuebingen, Baden-Wuerttemberg, 
Germany) according to the German Animal Welfare Act (TierSchG § Abs. 1) and 
were performed according to institutional guidelines. 
2.3.2 Helios® Gene Gun infection  
2.3.2.1 Precipitation of CRPV DNA to gold particles 
For the infection of rabbit skin, CRPV DNA was purified with the EndoFree® Plasmid 
Maxi Kit and adjusted to approx. 1 µg/µL. Each DNA was mixed with 50 mg gold 
particles, 100 µL of 0.05 M spermidine. Samples were then sonicated (4× 10 sec), 
incubated with 100 µg CRPV DNA and precipitated with 100 µL of 1 M CaCl2 at room 
temperature for 10 min. The DNA-coated gold particles were washed 3 times with 
100% ethanol and were stored in 6 mL of 100% ethanol at - 20°C. 
For dilutions of CRPV DNA, the start concentration of CRPV DNA was 1 μg/μL 
followed by different dilutions. Four different concentrations of CRPV DNA from 1 
µg/μL to 10 ng/μL were generated and gold particles were coated. In order to have a 
high gold-coating efficiency, CRPV DNAs were diluted using pUC19 plasmids to 
keep the final concentration of 100 μg/100 μL for each dilution according to the 
manufacturer’s instructions of the Helios® Gene Gun system. 
2.3.2.2 Preparation of cartridges for Helios® Gene Gun System 
Cartridges were prepared using the Tubing Prep Station according to the 
manufacturer’s instructions. Briefly, the Tefzel® tube was flushed with nitrogen gas. 3 
mL of the CRPV coated gold particles in ethanol were injected into the tube. After 
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precipitation of the gold particles, the ethanol was removed. By suction and rotating 
the hose, the gold particles were uniformly distributed on the inner tube surface. The 
tube was dried for 5 minutes and was cut into 1 cm long cartridges using the Tubing 
Cutter. The cartridges were then stored at 4°C. 
2.3.2.3 Delivering of CRPV DNA by Helios® Gene Gun System 
NZW outbred rabbits were anesthetized with a mixture of Ketamine and Sedator®. 
The fur on the rabbits’ back was trimmed with an electric clipper and wet-shaved with 
a razor blade. All sites to be infected were marked with black tattoo ink. For each 
site, sandpaper treatment was conducted to disrupt the upper layer of the skin, and 
then 10 cartridges were delivered to the wounded tattoo marked site using the 
Helios® Gene Gun System with 350 psi injected pressure.  
2.3.3 Sample collection from rabbits 
A collection of a skin punch biopsy was performed under general anesthesia 
described above. Standard 3 mm and 6 mm biopsy punches and a sterile disposable 
scalpel were used to remove the skin tissue. Suturing of the wound was performed 
when using 6 mm biopsy punches. Hemostasis was achieved by applying pressure 
for several minutes with a sterile swab. Once the skin tissue biopsy was removed, it 
was wrapped in aluminum foil and was snap-frozen in liquid nitrogen, then stored at - 
80°C.  
Rabbits were euthanized at the end of experiments via administering 200 mg/mL 
solution of potassium chloride directly to the heart. Following confirmation of death, 
the lymph nodes and important organs such as lung, liver, and spleen were collected 
and snap-frozen in liquid nitrogen, then stored at - 80°C. 
2.3.4 Drug-induced immunosuppression in NZW rabbits  
Cyclosporin A (CsA) (Sandimmun® 50 mg/mL) and Dexamethasone (Dex) 
(Dexadreson® sodium, 2 mg/mL) were injected subcutaneously into the neck fold of 
the rabbits. The treatment was previously described (106). The optimized doses for 
immunosuppressive drug administration in this study were 7.5 mg/kg CsA three times 
per week (Monday, Wednesday, and Friday) and 0.15 mg/kg Dex twice per week 
(Tuesday and Thursday). The physical condition was vigorously monitored at each 
treatment to ensure rabbits were maintaining body weight, as well as food and water 
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intake. Immunosuppressed rabbits were kept in individual cages in a separate SPF 
(Specific-pathogen-free) room and were fed with autoclaved water.  
2.3.5 Flow cytometry (FACS)  
Flow cytometry used for quantification of peripheral blood lymphocytes has been 
previously described (106, 169). In brief, at least 1 mL of whole peripheral blood was 
collected from the rabbit’s ear vein using heparin coated syringes. 500 µL blood was 
diluted with 4.5 mL FACS buffer and centrifuged at 300×g for 5 min at room 
temperature. After removal of the supernatant, red blood cells were lysed in 10 mL 
standard Ammonium-Chloride-Potassium (ACK) buffer for 10 min at room 
temperature with gentle agitation. The lysed red blood cells were separated by 
centrifugation at 300× g for 5 min. leucocytes were re-suspended in the FACS buffer 
and were distributed into 200 µL for each reaction. The sample was incubated with 
10 µL of each FITC-conjugated mAb: mouse anti-rabbit T lymphocytes (TLC, also 
known as CD5), CD4+ and CD8+, mouse IgG1 negative control, and mouse IgG2a 
negative control at 4°C for 30 min. After 3 times wash (300× g for 5 min) in FACS 
buffer, the leucocytes were resuspended in 800 µL FACS buffer. The stained T-
lymphocytes membrane markers were determined by one color flow cytometry, which 
was performed using an FACSCalibur. For each FACS measuring, 100,000 cells 
were sorted. FACS data was analyzed using CellQuest Pro software (FIG 2.3.1). The 
concentration of T-cells in PBMCs was calculated by the following equation:  
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FIG 2.3.1 Example of the FACS analysis of rabbit CD5 cells (T lymphocyte, TLC). Red 
blood cells were lysed in whole blood samples and subjected to FACS analysis using 
anti- rabbit CD5 and control IgG1. A: Lymphocytes were gated following examination of 
density plots. B, C, D: For each detection, 100,000 cells were sorted. The stained T cell 
population was determined and normalized to IgG1 controls.  
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2.3.6 Ultra Violet light treatment 
Rabbits were anesthetized and shaved, then were placed under the UV source at a 
distance of 15 cm from side back skin. The intensity of UV was measured by a UVX 
radiometer sensor and calculated by the equation, J= W.s with respect to the light 
source. The non-irradiated skin was covered by photoresist plastic sheeting. A UVB 
lamp (312 nm, 15 W VL-115.M) which stably emitted light at 1000 µW/cm2 at a 
distance 15 cm was used. The doses of UVB treatment were from 10 to 800 mJ/cm2 
and were calculated by the exposure times ranging from 10 to 800 seconds. A UVA 
lamp (365 nm, 30 W VL-215.L) which stably emitted light at 2300 µW/cm2 at a 
distance 15 cm was used. The dose of 5 mJ/cm2 UVA treatment were calculated by 
the exposure time 36 min 14 s, and the dose of 1 mJ/cm2 UVB treatment were 
calculated by the exposure time 16 min 40s. 
2.4 Collection of clinical data and Statistical analysis  
At each examination, the number, location and dimensions (length, width, height) of 
each papilloma were recorded. The data were used to calculate the papilloma 
volume (V), V= 4π/3× length/ 2× width/ 2× height/2 (170) and the papilloma specific 
growth rate (SGR), SGR = ln (V2/V1) /(t2 - t1) (171). Statistical analyses were 
conducted using GraphPad Prism 5 software (La Jolla, USA). If the data sets were 
not normally distributed, the Mann-Whitney t-test was used to determine significant 
differences (p < 0.05). If the data sets can be transformed to a normal distribution 
model then the logarithmic transformation was used for the justification, and the 
unpaired Student’s t-test was conducted to determine significant differences (p < 
0.05). 
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2.5 Overview of the animal experiment 
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3 RESULTS 
3.1 CRPV latent infection animal model 
3.1.1 Development of RT-qPCRs for the quantification of latent CRPV genome 
and transcripts 
Highly sensitive SYBR Green I based RT-qPCRs targeting various viral genes were 
established and evaluated for the detection of a minimum of 1 copy of CRPV genome 
per reaction. Primers were designed to specifically target CRPV gene sequences. 
The melting curves of each RT-qPCR showed that all primers were specific to CRPV. 
Detection of serially diluted standard CRPV plasmids showed that these RT-qPCRs 
were able to detect at least 4 copies of CRPV DNA per reaction (Table 3.1.1). The 
primer set SE6/LE6 showed the highest specificity among the primer sets in rabbit 
skin biopsies, which was then used for CRPV DNA quantification in the following 
experiments.  
Table 3.1.1 Summary of the sensitivities of the RT-qPCR  
Primers Standard curve Efficiency 
value 
Cycles to 
detect of one 
copy DNA 
One copy 
detect ratea 
 
Limit of 
detection b 
(copies) 
SE6/LE6 Y = -3.34x + 38.3 - 3.34 39 60% 4  
LE6 Y = -3.57x + 39.7 - 3.57 40 50% 4 
E1^E4 Y = - 3.37x + 41.8 - 3.37 42 30% 10 
GAPDH Y = - 3.64 + 40.5 - 3.64 41 30% 6 
Note: a successful detection of one copy DNA standard plasmid in 10 repeats.  
b 90% successful detection of certain copy numbers of DNA standard plasmid in 10 repeats.  
The CRPV E1^E4 primers, which have been shown to detect all viral early mRNAs 
as previously described (161) were used for the quantification of viral transcripts. As 
tested in this study, this TaqMan probe based CRPV E1^E4 RT-qPCR showed high 
sensitivity in detecting viral transcripts as low as 1 viral mRNA copy per reaction. 
The ratio of CRPV DNA copy to cell number was determined by RT-qPCR using the 
SE6/LE6 primer set and CP values were normalized to the rabbit GAPDH gene copy 
number per cell. The average rabbit GAPDH gene copy number per cell was 
determined by quantifying GAPDH genes in the rabbit-derived AVS cell line. The 
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results showed that the GAPDH primer pair used in this study detected 
approximately 17 ± 4 (Median ± SD) copies of GAPDH “homologous” sequences per 
rabbit cell. Therefore, 17 copies of GAPDH per rabbit cell were used for the 
normalization of viral DNA copy number to cell number in the following experiments.  
3.1.2 Development of a rabbit model for CRPV latent infection  
It has been shown that CRPV DNA can persist either after low-titer virus infection or 
after lesion regression (109, 111). In this study, a low dose of viral DNA infection was 
used to establish an in vivo CRPV latent infection model in NZW rabbit.  
We first defined a CRPV DNA dose which consistently induces asymptomatic 
infections at the majority of the infected sites. Three NZW rabbits were cutaneously 
infected with serially diluted CPRV DNA (FIG 3.1.1 A) via the Bio-rad Helio Gene 
Gun system. Rabbits were anesthetized and were shaved before infection. All sites 
to be infected were marked with black tattoo ink. Ten weeks p.i. – which is the time 
frame by which papilloma formation is generally completed, we found that 40 ng 
CRPV DNA resulted in 29.2% (7/24) papilloma formation (FIG 3.1.1 B). Infection of 
the skin with CRPV was very well tolerated by all NZW rabbits with no apparent 
adverse effects on their health and weight gain. 
To investigate whether the viral DNA was retained in the asymptomatic infected site, 
skin biopsies were taken from asymptomatic tattoo ink-marked areas 15 weeks post 
infection and after euthanization (up to 14 months p.i., Table S1). CRPV DNA was 
quantified using highly sensitive RT-qPCR. We determined that a median of 7 copies 
of CRPV DNA per 1000 cells were present at the asymptomatic sites 15 weeks post 
infection and 14 copies of CRPV DNA per 1000 cells after euthanization. However, 
there is no significant increase between 15 weeks post infection and after 
euthanization. The level of viral DNA detected in skin biopsies was approximately 3 
to 5 log-folds lower compared to the median viral DNA copies in papillomas, which 
are approximately 68 copies per cell. No viral DNA was detected in normal 
uninfected skin biopsies (FIG 3.1.1 C) 
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FIG 3.1.1 Low-dose CRPV infection leads to reduced papilloma induction and latent infection. (A) 
Schematic of the infection pattern on a NZW rabbit’s back skin. Each number in the drawing 
represents one site of infection. (B) Papilloma formation at 10 weeks p.i.. Visible papillomas 
occurred within 10 weeks p.i.. There was no formation of new papilloma after 10 weeks. (C) 
Persistence of CRPV DNA copy number following latent infection. Papilloma samples were taken 
from rabbit 1, 2, 3 after euthanization. Skin biopsies were taken from rabbit 1, 2 and 3. Each dot in 
the graph represents one sample. Papilloma n=10, normal skin n=6, asymptomatic sites (15w) 
n=17, asymptomatic sites (end) n=18. The Mann-Whitney test was conducted for the statistical 
significant test. 
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3.1.3 Persistence of CRPV genomes in latently infected sites  
To determine for how long the viral DNA persists in latently infected skin sites, skin 
biopsies were taken sequentially from asymptomatic infected sites from 6 rabbits 
(rabbit 1, 2, 3, 14, 15, and LAT4; see Table S1), and were subjected to RT-qPCR 
quantification. Collectively, one-month p.i. we detected a median viral copy number 
of approximately 10 copies per 1000 cells. This number did not significantly change 
(p >0.05) during the following sequential measurements spanning a total of 14 
months (15 copies per 1000 cells). No viral DNA was detected in normal skin 
biopsies (FIG 3.1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 3.1.2 CRPV DNAs persisted long post infection in asymptomatic low dose infected site. CRPV 
DNA copy numbers were normalized to 17 copies of GAPDH copy number per cell. Each dot in the 
graph represents one sample. Papillomas n =16 (Median = 62 copies/cell), normal skin n =10, 1 
month n =11 (Median =10 copies/ 1000 cells), 4 months n = 15 (Median= 9 copies/1000 cells), 8 
months n =28 (Median = 6 copies/1000 cells), 12 months n=13 (Median = 12 copies/1000 cells), 14 
months n=13 (Median = 15 copies/1000 cells). The Mann-Whitney test was conducted for the 
statistical significant test. 
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In this study, 21 rabbits were infected with various doses of CRPV DNA see Table 
S1. The CRPV DNA concentration delivered by the Gene Gun correlates with the 
efficiency of papilloma induction (FIG 3.1.3). In total, 223 of infected asymptomatic 
skin biopsies were obtained from 20 rabbits, except for rabbit 10 which developed 
100% of papillomas at all infected sites (Table S1). Altogether, 88% (198/223) of the 
sites were found containing CRPV DNA up to 24 months p.i. (Table 3.1.2). The 
average median level of the CRPV DNA in the asymptomatic site was 13 copies per 
1000 cells (FIG 3.1.4).  
In addition, low levels of CRPV E1^E4 transcripts were detectable at an average of 
one copy per 10,000 GAPDH mRNAs only in 32% (17/53) of the skin biopsies (Table 
3.1.2).  
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FIG 3.1.3 The amount of CRPV DNA correlates with papilloma induction. The original data are 
shown in Table S1. The dashed lines represent the 95% Confidence Intervals. The R2 represents 
the regression coefficient of determination, meaning 68% of the variance in the response variable 
can be explained by the explanatory variables, and the remaining 32% can be attributed to 
unknown, lurking variables or inherent variability. 
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Table 3.1.2 Summary of samples detected in this study 
Sample  
Viral DNA 
 
Viral transcripts  
Total Positive* Percentage Total Positive Percentage 
Normal skin 58 0 0  21 0 0 
Latently 
infected skin  
223 198 88%  53 17 32% 
*A sample was considered positive only when the Tm value of the qPCR was the same as the positive 
control and the Cp value was < 37. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.4 Ex vivo expansion of latently infected cells  
We isolated primary rabbit skin cells from 16 CRPV latently infected sites and 6 
normal skin sites of 3 rabbits. To isolate both the epithelial cells and hair follicle cells, 
the whole skin tissue was subjected to primary cell isolation (FIG 3.1.5A). After the 
second passage, CRPV DNA was detected in 12 out of 16 latently infected skin 
FIG 3.1.4 CRPV DNA persisted in 223 asymptomatic infected sites of 20 rabbits. CRPV DNA copy 
numbers were normalized to 17 copies of GAPDH copy number per cell. Each dot in the graph 
represents one sample. The red line indicates the average median level of CRPV copies, which is 
0.01323. The viral DNA copy numbers of 49 samples are above 6 copies per 100 cells.  
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cultures, with 5 copies/cell in average (FIG 3.1.5 B). Viral DNA was not found in the 6 
sets of normal skin expanded cells. Three of the CRPV DNA positive primary cell 
cultures had been found to express low levels of E1^E4 transcripts. However, we 
were unable to culture these primary cells beyond passage 6 (FIG 3.1.5 C). The 
expanded primary rabbit cell populations did undergo very slow cell division. In order 
to find out which type of rabbit epithelial stem cells that survived during the ex vivo 
expanding, we tried to look for potential markers that might identify the type of cells. 
Previously, we have shown that during productive infection, the primary target cells of 
CRPV are located in self-renewable HF stem cells (78). Therefore, we used one of 
the potential biomarkers - the cytokeratin 15 (K15) protein which is used as a marker 
of stem cells of the hair-follicle bulge to identify the stem cells  (172). Using 
immunofluorescence staining, we found 24% of the expanded cells express K15 in 
the expanded cell culture (FIG 3.1.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 3.1.5 Ex vivo culture of infected cells. (A) Experimental set up of expanding latently infected 
skin cells ex vivo. (B) RT-qPCR quantification of CRPV DNA in the normal skin cell culture (n= 8) 
or latently infected skin cell culture (n= 12) passage 3, 10 days after explantation. (C) 
Representative example of an ex vivo culture of latently infected skin tissue #7 which was taken 
18 months p.i. from rabbit LAT4 during autopsy (Table S1). 
A 
B 
C 
No
rm
al 
ski
n
La
ten
tly 
inf
ec
ted
 sk
in
0
5
10
15
20
25
p < 0.003
C
R
PV
 D
N
A 
co
pi
es
 / 
C
el
l
in
ex
 v
iv
o
ex
pa
nd
ed
 c
el
ls
RESULTS 
47 
 
 
 
 
 
 
 
 
3.1.5 Determination of the methylation status of latent viral genomes 
To investigate whether latent viral gene expression is regulated by levels of DNA 
CpG methylation during PV latency, we performed bisulfite-mediated methylation 
PCR amplification and sequencing to detect potential CpG methylation in latent viral 
DNAs. We first designed three methylation specific nested primer sets that cover the 
entire region of the CRPV URR (Methprimer 1 and 2, FIG 3.1.7) as well as the early 
promoter region of CRPV E6 (Methprimer 3, FIG 3.1.7). The inner PCR amplicons 
were then cloned, and at least 10 positive clones were sent for sequencing. In total, 
we analyzed five latently infected skin sites taken from the tattoo marked skin of 5 
rabbits (rabbit 1, 2, 3, 4 and 5, see Table S1), as well as samples from one papilloma 
and the pLAII-CRPV recombinant plasmid. The results of the sequence alignments 
showed that 99% of cytosines were converted to thymines. However, no CpG 
methylation site was found in any of the clones.  
Interestingly, two bacterial DNA methylase (dcm ,CCAGG) methylated sites (position: 
7795^7799 and 115^119) have been found in 48% (24/50) and 34% (17/50) of the 
above sequenced clones, respectively (Table 3.1.3), which originates from DH5α E. 
coli used for amplification of the viral genome plasmid pLAII-CRPV before inoculation 
of rabbit skin. The dcm methylations were lost completely in sequenced clones of 
rabbit 3 and LAT 4  fourteen months p.i. (Table 3.1.3). CpG methylations, as well as 
dcm methylations, were not detected in papillomas. In contrast, the two dcm sites 
were found 100% methylated in the original pLAII-CRPV plasmid preparation (Table 
3.1.3). 
FIG 3.1.6 Immunofluorescence staining of ex vivo expanded cells from latently infected skin 
sites with K15 antibody.  
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In addition, by sequence analysis, we found that a total of eleven CCAGG and twelve 
CCTGG sequences exist in the pLAII-CRPV genome. It is known that almost all 
commonly used cloning strains such as DH5α E. coli are dcm+. As it is unclear 
whether bacterial DNA methylation affects viral infection, we therefore looked for E. 
coli strains that do not methylate dcm. We found one strain - SCS110 competent 
cells which is ideal for preparing plasmid-free of dam or dcm methylation(173). We 
compared the methylation status of a CRPV DNA preparation from the dcm+ DH5a 
strain to a preparation from the dcm- SCS110 strain. Indeed, the pLAII-CPRV 
produced in DH5a E. coli were completely methylated by dcm DNA methylases (FIG 
3.1.8). In contrast, the DNA produced by the SCS110 strain was not methylated (FIG 
3.1.8).Therefore, the SCS110 competent cells were used for the production of viral 
DNA in the following experiments.  
 
 
 
 
 
 
 
 
 
FIG 3.1.7 Cartoon of the motifs of CRPV URR-LE6 region and methylation primers amplification. 
Two dcm sites (CCAGG) were observed in some of the clones. E2BS: E2 binding site, PL: late 
promoter, AP1: Activator protein 1, LE6: long E6, SE6: short E6.  
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Table 3.1.3  Two dcm methylations in latently infected samples 
Rabbit 
Latent skin methylated clone/total clones 
(Percentage of dcm methylations) 
7795^7799 115^119 
Rabbit 1 5/10 (50%) 0/10 (0) 
Rabbit 2 9/10 (90%) 10/10 (100%) 
Rabbit 3 0/10 (0) 0/10 (0) 
Rabbit LAT 4 1/10 (10%) 0/10 (0) 
Rabbit 5 9/10 (90%) 7/10 (70%) 
pLAII-CRPV 10/10 (100%) 10/10 (100%) 
Papilloma 0/10 (0) 0/10 (0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.6 Determination of the physical status of latent CRPV DNAs 
To further determine the physical status of the persistent viral DNA, we performed 
rolling circle amplification (RCA) experiments. The RCA can specifically amplify 
circular DNAs (174) (FIG 3.1.9 A). The RCA experiment was initially performed 
FIG 3.1.8 The methylation status of CRPV DNAs in the dcm+ DH5a strain SCS110 strain. (A) 
Digested by BamH1 which cuts the viral genome without preference of any methylations. (B) 
Digested by PspGI which specifically cuts the non-methylated dcm (CCA/TGG) sites. 
A B 
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according to the manufactures’ instruction of TempliPhi 100 Amplification Kit. 
However, the sensitivity was low, which is why we optimized the protocol by adding 
an additional specific viral primer set for SE6/LE6 into the reaction. After 
optimizations, the RCA detects at least 0.1 pg of pLAII-CRPV pure plasmid DNA (FIG 
3.1.9 B). Additionally, the RCA method showed no amplification of CRPV genomes, 
which are “head-to-tail” integrated into the host genome in Vx2 cells (FIG 3.1.9 B).  
The RCA method was applied to amplify viral DNA, which was extracted from latently 
infected skin biopsies. The results showed that RCA amplified CRPV DNA in one of 
the latent samples (FIG 3.1.9 C) indicating that complete episomal CRPV genomes 
were present in at least in one of the latently infected skin tissues. However, due to 
the low sensitivity of RCA per se, only samples with higher copy numbers of CRPV 
DNA (above one copy per cell) were detected. The majority of the viral DNA in latent 
samples was undetectable (FIG. S1).  
In addition, full-length CRPV E1 and E2 were detected in latently infected skin 
samples containing high viral DNA loads (FIG 3.1.10). Sequencing results of the 
positive bands of E1 and E2 showed 100% matches to the CRPV sequences. 
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FIG 3.1.9 RCA amplified latent viral DNA. (A) The principle of RCA amplification, adapted from 
http://www.mclab.com/RCA-DNA-Amplification-Kit.html. (B) Test of the sensitivity and specificity of 
RCA amplification using serial diluted standard pLAII-CRPV plasmid. M: GeneRuler 1 kb plus DNA 
lander. (C) RCA amplifed DNA in high viral copy samples. M: 1 kb maker, a: CRPV-pLAII plasmid 
control, b: RCA amplified CRPV-pLAII plasmid, c: RCA amplified DNAs from Vx2 cells, d-g: RCA 
amplified DNAs from latently infected skin biopsies. The arrows indicate the positive band.  
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3.2 The effect of ultraviolet (UV) light on CRPV latent infection 
It has previously been reported that low-dose CRPV infection could be facilitated by 
UVB light in domestic Dutch-Belted rabbit model system shortly after injection (110). 
Other latent viruses, for example, herpes simplex virus can also be activated by UV 
light (175). We have demonstrated that CRPV DNA persisted in the infected sites for 
more than 14 months without causing papillomas (Table 3.1.2). We, therefore, asked 
whether UVB light affects the persistent infection of CRPV infection. 
3.2.1 Establish UV light irradiation conditions for NZW rabbit model 
To initially determine a suitable UVB intensity for the treatment of rabbit skin, we first 
established a model for UVB radiation of normal NZW rabbit skin (FIG 3.2.1 A) by 
using different UVB light intensities ranging from 120 mJ/cm2 to 800 mJ/cm2 (FIG 
3.2.1 B). The results showed that an intensity of 450 mJ/cm2 causes the normal 
rabbit skin sunburn symptoms such as reddening and peeling of the skin 3-day post 
radiation (FIG 3.2.1 B), but no severe symptoms such as blistering or edema. As UV 
radiation alone is a casual risk factor of skin tumor and to reduce the strong side 
effect of UV radiation, we selected an intensity of 200 mJ/cm2 for the following 
experiments.  
 
 
 
FIG 3.1.10 Detection of full length CRPV E1 and E2 in viral latency. (A) E2 full length detection. M: 
1 kb maker, N: negative control, 1 to 3 were latently infected samples from rabbit 9. (B) E1 full 
length detection. M: 1 kb maker, N: negative control, 1 to 3 were latently infected samples from 
rabbit 12. The viral copy numbers of the 3 samples were determined by RT-qPCR, which was 119 
copies/100 cells, 143 copes/ 100 cells, and 18 copies/ 1000 cells, respectively. 
M         N    1   2    3 M   1       2     3      N A B 
1500 bp 1173 bp 
1809 bp 1500 bp 
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FIG 3.2.1 Effect of UVB on normal rabbit skin. A, UVB lamp construction. The black plastic was 
tested to completely prevent UVB radiation from passing through, and was used to cover the other 
parts of the skin. The UV sensor was directly placed near the radiated area to measure the 
radiation intensity. The measurement results can be read on the radiometer. The distance 
between UVB lamp and the skin was 15 cm, which results in 1000 µW/cm2. The intensity of UVB 
was calculated by the equation: J=Ws. B, Effect of the four intensities of UVB on normal rabbit 
skin within one week. 
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A 
B 
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3.2.2 The role of UVB light radiation on papilloma formations induced by low 
dose CRPV infection  
In this experiment, four rabbits were infected with 34 ng of CRPV per site with the 
infection pattern shown in FIG 3.2.2 A. Additionally, the cutaneous injection of the 
pUC19 plasmid was used as a mock control for UVB treatment. UVB light was 
applied to three of four latently infected rabbits at days 12 and 15 (FIG 3.2.2 B). 
Biopsies were taken at different time points to monitor the amount of viral DNA. We 
found that the CRPV DNA persisted and observed a slight but insignificant increase 
after the second UVB irradiation (FIG 3.2.2 C). Visible papillomas appeared within 8 
weeks post infection on all four latently infected rabbits. Papilloma formation rate was 
slightly increased and with high variability, but not significant in the UVB-treated 
group (27.78% UVB-treated sites versus 20.08% untreated site). Despite the same 
treatments, rabbit LAT2 developed fewer papillomas (2/24) compared to rabbits LAT 
1 (10/24), LAT3 (8/24) and LAT4 (8/24) (Table 3.2.1, FIG 3.2.2 D). No papilloma 
appeared at pUC19 mock inoculated sites. 
Table 3.2.1 Summary of papilloma formation within 8 weeks post-infection. (++ 
indicates two UVB treatments) 
Rabbit ID Treatment 
Number of positive sites/ number of infected 
sites 
Efficiency of CRPV 
inducing papilloma 
CRPV pUC 19 
LAT 1 UVB ++ 10/24 0/8 41.67% 
LAT 2 UVB ++ 2/24 0/8 8.33% 
LAT 3 UVB ++ 8/24 0/8 33.33% 
LAT 4 UVB - 5/24 0/8 20.08% 
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FIG 3.2.2 UVB irradiation of latently infected sites. (A) The infection pattern on the back of 
rabbits. (B) Schematic overview of the study design. (C) Copy number of CPRV DNA following 
infection. Each dot represents one sample. Six samples were analysis from each group. The 
data was log-transformed, and then the unpaired t-test was conducted for the statistical 
significant test. (D) Papilloma formation within 8 weeks post-infection. + indicates one UVB 
treatment. 
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3.2.3 The effect of UVB light radiation on CRPV latent infection 
In general, spontaneous formation of visible CRPV induced papillomas is completed 
within 8 to 10 weeks p.i (107). The sites, which harbor viral DNAs without lesions 
after 8 to 10 weeks post infection, were considered latently infected. The third UVB 
irradiation was applied to all four rabbits at the 8th-week post infection (FIG 3.2.3 A). 
We observed no new papilloma formation on all four rabbits in the following 8 weeks 
observation. Instead, two papillomas regressed on rabbit LAT 1 (FIG 3.3.5 and Table 
3.2.2). No papilloma appeared at pUC19 mock inoculated sites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIG 3.2.3 Papilloma formation within 9 weeks post-infection. All four rabbits were treated with 200 
mJ/cm2 UVB (UVB+). Photographs were taken after two weeks of the late UVB treatment.   
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Table 3.2.2 Summary of papilloma formation within 16 weeks post-infection. (+++ 
indicates three UVB treatments, + indicates one UVB treatment) 
 
3.3 Reactivation of latent viral infection by wound healing 
Mechanical irritation of rabbit skin prior to infection with CRPV virions or genomes 
enhanced infectivity, but it is not clear whether or not such treatment has an effect on 
latent CRPV reactivation (176). For this experiment, we irritated the asymptomatic 
sites which were infected with 40 ng CRPV DNA (FIG 3.1.1). The glass sand paper 
was used for scraping the infected site until the skin showed some redness. The 
irritations were performed directly on the tattoo ink marked areas where the viral DNA 
was inoculated. Irritation treatment was started 7 weeks p.i.. However, we observed 
a trend but not significant increasing of latent viral copy numbers and no appearance 
of new papillomas during six weeks of irritation treatment (FIG S2).  
3.4 Immunosuppression on CRPV latent infection 
Drug-induced immunosuppression has been proposed to be one of the risk factors 
for the reactivation of latent PV infection in OTRs (9, 83). This experiment was 
designed to test this hypothesis. 
3.4.1 Establishment of drug-induced immunosuppression on NZW rabbits  
To establish drug-induced immunosuppression conditions on domestic NZW rabbits, 
we first administered triweekly CsA (15 mg/kg) and bi-weekly Dex (0.5 mg/kg) to two 
normal rabbits as previously described (106). The body weight of the rabbits was 
meticulously monitored daily to ensure that animals are maintaining their body 
weight, as well as food and water intake. The peripheral blood mononuclear cells 
(PBMCs) were taken from the ear vein of the rabbit every other week post-
Rabbit ID Treatment 
Number of positive sites/ number of infected 
sites 
Efficiency of CRPV 
inducing papilloma 
CRPV pUC 19 
LAT 1 UVB +++ 8/24 0/8 33.33% 
LAT 2 UVB +++ 2/24 0/8 8.33% 
LAT 3 UVB +++ 8/24 0/8 33.33% 
LAT 4 UVB + 5/24 0/8 20.08% 
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immunosuppression, and were subjected to FACS analysis. We found that the 
rabbits’ body weight decreased sharply after four weeks of drug administrations, and 
one rabbit had to be euthanized because it lost more than 20% of its body weight 
(FIG 3.4.1 A). According to our animal experiment approval, the experiment had to 
be terminated due to over 20% of weight loss. T-cells of both rabbits were 
significantly reduced two weeks post-immunosuppression (FIG 3.4.1 B, C).  
Hence, we reduced the drug dosages by half to 7.5 mg/kg CsA three times per week 
(Monday, Wednesday, and Friday) and 0.15 mg/kg Dex twice per week (Tuesday 
and Thursday). Three of four rabbits were administered with CsA and Dex. The 
health status of all rabbits was closely monitored at each treatment. The PBMCs 
were subjected to FACS analysis of T-cell populations using the T-cell markers TLC, 
CD4+ and CD8+. After 10 weeks of immunosuppression, we observed that the 
rabbits’ body weight maintained at a relatively constant level (FIG 3.4.2 C). We still 
found significant reductions of T-cell counts starting two weeks post-
immunosuppression. No significant difference in T-cell counts between the lower 
dosages and the initial high-dose treatment was found (FIG 3.4.2 C, FIG 3.4.2 B).  
In addition, rabbit LAT2 died with unexpected lung infections. To avoid further 
complications, we specified our protocol for the drug-induced immunosuppression of 
NZW rabbit as follows:    
Rabbits to be immunosuppressed need to be kept in a separate SPF 
immunosuppression room and fed with autoclaved water and irradiated hay.  
To avoid cross contamination, the experimenter has to change lab coat, gloves, foot 
and head cover, and disinfect when entering the immunosuppression room.    
The body weight, food and water intake of immunosuppressed rabbits need to be 
checked before each treatment.  
7.5 mg/kg CsA three times per week (Monday, Wednesday, and Friday) and 0.15 
mg/kg Dex twice per week (Tuesday and Thursday) are multi-point injected 
subcutaneously into the nuchal fold of the rabbits.  
During the course of immunosuppression, when the rabbit lost body weight ≥10% in 
5 days, the administration of the drugs should be reduced (e.g, 3.5 mg/kg CsA and 
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0.07 mg/kg Dex). If the body weight was still decreasing, the treatment had to stop 
until the rabbit regains 10% weight. The treatment had to be terminated once the 
rabbit loses over 20% of its initial baseline weight.  
Approximately 1 ml of PBMCs was taken via the rabbit’s ear vein without anesthesia 
every two weeks after immunosuppression and then is processed for FACS analysis 
within 18 hrs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 3.4.1 Drug-induced immunosuppression on NZW rabbits. (A) Body weight of 
immunosuppressed rabbits. (B) Representative FACS analysis results. IgG 2a is negative/isotype 
control. (C) FACS analysis of T cells in PBMCs of immunosuppressed rabbits. The week 0 means 
the PBMCs were taken one day before the immunosuppression. 
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FIG 3.4.2 Establishment of drug-induced immunosuppression on NZW rabbit model. (A) Body 
weight of immunosuppressed rabbits. Rabbit LAT2 died due to unexpected lung infection. (B) 
FACS analysis of T cells in PBMCs of immunosuppressed rabbit LAT1, LAT2, and LAT3, and non-
immunosuppressed rabbit LAT4. The week 0 means the PBMCs were taken one day before the 
immunosuppression. 
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3.4.2 The effect of immunosuppression on CRPV latent infection  
After establishing the immunosuppressive treatment conditions, we investigated 
whether CRPV infections were controlled by decreased immunological control. We 
infected 4 rabbits with low dose 12 ng CRPV DNA and then administered rabbit 7 
and 8 with immunosuppressive drug CsA and Dex one week p.i., and with the rabbit 
5 and 6 seven weeks p.i. (Table 3.4.1). The immunosuppressed rabbits slowly 
gained weight (FIG 3.4.3 A). T-cell counts were significantly decreased after 2 weeks 
of immunosuppressive treatment and were maintained at a low level (FIG 3.4.3 B). 
Skin biopsies were taken 6 weeks, 11 weeks and 17 weeks post-
immunosuppression. We found that the viral DNA copy number of samples from 11 
weeks and 17 weeks post-immunosuppression showed a significant increase 
compared to that of 6 weeks after immunosuppression (FIG 3.4.3 C). There were two 
samples both from rabbit 8 that had no increase of viral copy number 6 weeks post 
immunosuppression but showed significant higher viral DNA copy number (> 1 
copy/cell) above the average (7 copies/100 cells) 11 weeks and 17 weeks post 
immunosuppression respectively (FIG 3.4.3 C). The papilloma formation on all 4 
rabbits was completed within 8 weeks. There was no difference in terms of papilloma 
formation whether the immunosuppression started one-week p.i. or 7 weeks p.i. 
(Table 3.4.1). Furthermore, there was no appearance of new papillomas during 5 
months after the cessation of immunosuppression (Table 3.4.1). 
Table 3.4.1 Papilloma counts following low viral dose infection and immune-
suppression  
Rabbit 
Infected 
dose 
Immunosuppression start 
Treatment 
duration 
(weeks) 
Papilloma positive/total 
infected spots  
(Weeks p.i.) 
2 weeks p.i. 7 weeks p.i. Week 10 Week 20 
Rabbit 5 12 ng 
 
+ 11 1/32 (3.13%) 1/32 (3.13%) 
Rabbit 6 12 ng  + 11 3/32 (9.38%) 3/32 (9.38%) 
Rabbit 7 12 ng +  17 3/32 (9.38%) 3/32 (9.38%) 
Rabbit 8 12 ng + 
 
17 1/32 (3.13%) 1/32 (3.13%) 
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FIG 3.4.3 Drug-induced immunosuppression elevates latent viral DNA copy number. (A) The body 
weight during treatment of the rabbits. (B) FACS analysis of TLC, CD4+ and CD8+ populations of 
the PBMCs of immunosuppressed rabbits. (C) The quantification of CRPV DNA copy numbers in 
latently infected skin following immunosuppression. Each dot represents one sample. The data was 
log-transformed, and then the unpaired t-test was conducted for the statistical significant test. 
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3.4.3 The effect of CsA based immunosuppression on papillomas formation 
CRPV induced papillomas follow a highly predictable development. Papillomas 
appear earliest 3 - 5 weeks after inoculation, and the formation is virtually complete 
by 8 to 10 weeks (107). Ten weeks after infections, the infected sites without visible 
lesions are considered latent infection. In this experiment, we infected 5 rabbits with 
a high dose (3.8 µg/ site) of CRPV DNA and immunosuppressed 3 of these rabbits 
starting 2 weeks p.i. (Table 3.4.2). The body weight of all immunosuppressed rabbits 
was constantly growing but slower compared to controls. The efficiency of papilloma 
formation in the immunesuppressed group is highly variable, but not significantly 
different from the control group (p = 0.1836). Interestingly, during the latent period, 
the appearance of 2 new papillomas (Papilloma 1 and 2) 15 weeks p.i. (13 weeks 
after immunosuppression) and the papilloma #3 appeared 18 weeks p.i. (16 weeks 
after immunosuppression) on the rabbit 11 in the immunosuppressed group was 
highly unusual (FIG 3.4.4 A, Table 3.4.2), which was not observed in control rabbits. 
As shown by FACS analysis, T-cells were significantly decreased after 2 weeks of 
immunosuppression and were maintained at a low level (FIG 3.4.4 B). The 
quantification of the viral DNA in latently infected biopsies from all 3 
immunosuppressed rabbits showed higher viral copy numbers (> 1 copy/ cell) in 4 
out of 18 biopsies above the average (4 copies/ 100 cells) 16 weeks post-
immunosuppression (FIG 3.4.4 C). The total number of latently infected sites, which 
harbor increased viral DNAs in the immunosuppressed group was significantly higher 
compared to the controls (FIG 3.4.4 C). There was no formation of new papillomas 
within the following 5 months of observation. 
Table 3.4.2 Papilloma counts following high viral dose infection and immuno-
suppression 
Rabbit Immunosuppression treatment 
Infected dose of 
CRPV DNA 
Papilloma positive/total infected spots 
(Weeks post infection) 
Week 10 Week 20 
Rabbit 9 - 3.8 µg 13/16 (81.25%) 13/16 (81.25%) 
Rabbit 10 - 3.8 µg 16/16 (100%) 16/16 (100%) 
Rabbit 11 + 3.8 µg 7/16 (43.75%) 9/16 (56.25%) 
Rabbit 12 + 3.8 µg 13/16 (81.25%) 13/16 (81.25%) 
Rabbit 13 + 3.8 µg 6/16 (37.5%) 6/16 (37.5%) 
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FIG 3.4.4 Drug-induced immunosuppression facilitates the onset of papilloma development and 
elevates viral copy numbers in high viral dose infection. (A) Three papillomas appeared during the 
latent period following 13 weeks immunosuppression (papilloma 1, 2) and 16 weeks 
immunosuppression (papilloma #3) on rabbit 11. (B) FACS analysis of the TLC, CD4+ and CD8+ 
T-cell populations in the peripheral blood of all three immunosuppressed rabbits. The mean ± SDs 
of T-cell populations at each time point were showed in the graph. (C) The quantification of CRPV 
DNA copy numbers in latently infected skin following 16 weeks immunosuppression. Each dot 
represents one sample. The data was log-transformed, and then the unpaired t-test was conducted 
for the statistical significant test. 
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3.4.4 The effect of immunosuppression on the susceptibility of low-dose CRPV 
infection 
We have shown that CsA-based immunosuppression had no effect on the 
papillomavirus infection whether the immunosuppression starts one-week p.i. or 7 
weeks p.i. (Table 3.4.1). In this experiment, we tested the effect of 
immunosuppression prior infection on the papilloma formation induced by low-dose 
CRPV infection. Five rabbits were infected with 10 ng CRPV DNA, of which three 
were immunosuppressed 2 weeks prior infection (FIG 3.4.5 A). The 
immunosuppression period lasted 16 weeks. T-cells were significantly decreased 2 
weeks after drug-induced immunosuppression and were maintained at a low level 
(FIG 3.4.5 B). The body weight of all immunosuppressed rabbits was constantly 
growing. The formation of all papillomas was virtually completed by week 10 p.i.. No 
new papilloma appeared within 20 weeks p.i.. The efficiency of papilloma formation 
10 weeks p.i. is highly variable, but not significantly different between the 
immunosuppressed group and the controls (p = 0.522) (Table 3.4.3).  
Table 3.4.3. Papilloma formation following immunosuppression and low viral dose 
infection. 
Rabbit 
Infected dose of 
CRPV DNA 
Immunosuppression 
2 weeks prior 
infection 
Papilloma positive/ total infected spots 
(weeks post infection) 
Week 10 Week 20 
Rabbit 14 42 ng - 1/16 (6.25%) 1/16 (6.25%) 
Rabbit 15 42 ng - 4/16 (25%) 4/16 (25%) 
Rabbit 16 42 ng + 0/16 (0) 0/16 (0) 
Rabbit 17 42 ng + 1/16 (6.25%) 1/16 (6.25%) 
Rabbit 18 42 ng + 2/16 (12.5%) 2/16 (12.5%) 
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FIG 3.4.5 The effect of immunosuppression on the susceptibility of low-dose CRPV infection. (A) 
Schedule of the CsA-based immunosuppression. (B) FACS analysis of the TLC, CD4+ and CD8+ 
T-cell populations in the peripheral blood of immunosuppressed rabbits 
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3.5 The effect of immunosuppression and UV light radiation on 
CRPV latent infection 
We have shown in Chapter 3.2 that irradiation using 200 mJ/cm2 of UVB light had no 
effect on latent CRPV infection, and in Chapter 3.4 we observed no increased tumor 
formation, but an increase of viral DNA copy numbers in latently infected skin sites 
upon immunosuppression. In this experiment, we intended to investigate the effect of 
the combination of the immunosuppression and the UV light radiation on the viral 
latent infection. 
3.5.1 Establish UVA/B light radiation conditions on NZW rabbit model 
As shown the low intensity of UVB (200 mJ/cm2) did not significantly affect CRPV 
latent infection. We then asked whether the UV-mediated sunburn effect might be 
required for the activation of latent viral infection. Therefore, as previously published 
(177) we applied a combination of UVB (1 J/cm2) and UVA (5 J/cm2) to two rabbits to 
test the sunburn effect. Indeed the UVA/B treatment caused severe reddening of the 
rabbits’ skin after 3 days, and peeling of the dead skin 2 weeks post radiation, but no 
severe symptoms such as blistering, or edema (FIG 3.5.1).  
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3.5.2 The effect of immunosuppression combined with UVA/B light on CRPV 
latent infection  
To address whether latent viral infection benefits from decreased immunological 
control and UV radiation, a combination of drug-induced immunosuppression and UV 
radiation was performed. The five rabbits used in this experiment were infected with 
42 ng CRPV (Table 3.4.3). The immunosuppressive drugs were applied to three of 
the five infected rabbits 20 weeks p.i. (FIG 3.5.2 A). The UVA/B radiation was then 
performed 2 weeks after immunosuppression (22 weeks p.i.) (FIG 3.5.2 A). The 
immunosuppression period lasted 16 weeks. The FACS analysis showed that the T-
cell counts were significantly reduced by drug treatment and were controlled at a low 
level during the experiment (FIG 3.5.2 B). Latently infected skin biopsies were taken 
FIG 3.5.1 Sun-burn effects on the NZW rabbit’s back skin under 5 J/cm2 of UVA and 1 J/cm2 of 
UVB.   
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16 weeks post-immunosuppression for analysis. As shown by RT-qPCR, the latent 
viral copy numbers were elevated in latently infected skin biopsies compared with the 
controls (FIG 3.5.2 C). No new papilloma appeared during or after the 
immunosuppression period (Table 3.5.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 3.5.2 The role of drug-induced immunosuppression and UV radiation in viral latent infection. (A) 
Schedule of the CsA-based immunosuppression and UV radiation. (B) FACS analysis of the TLC, 
CD4+ and CD8+ T-cell populations in the peripheral blood of all three immunosuppressed rabbits. The 
mean ± SDs of T-cell populations at each time point were showed in the graph. (C) The quantification 
of CRPV DNA copy numbers in biopsies of latently infected skin sites at 16 weeks of 
immunosuppression. Each dot represents one sample. The data was log-transformed, and then the 
unpaired t-test was conducted for the statistical significant test. 
 
0 2 4 6 8 10 12 14 16 18
0
2.0104
4.0104
6.0104
8.0104
1.0105
1.2105
1.4105
1.6105 TLC
CD4+
CD8+
Week after immunosuppression
C
el
ls
/m
L
A 
B C 
Co
ntr
ol
Im
mu
no
su
pp
res
sio
n+
UV
A/B
-4
-3
-2
-1
0
p= 0.0422
Lo
g 
(C
RP
V 
D
N
A 
co
pi
es
 / 
C
el
l)
Immunosuppression 
UVA/B 
2 w 14 w 
Rabbit 16, 17, 18 
Rabbit 14, 15 
20 w 
Gene Gun 
Infection 
RESULTS 
71 
Table 3.5.1. Papilloma formation following low viral dose infection, immune-
suppression and UVA/B radiation. 
Rabbit 
Infected 
dose of 
CRPV DNA 
Immuno-
suppression 
treatment 
UVA(5J/cm2) 
UVB (1J/cm2) 
Papilloma positive/total infected spots 
(weeks post infection) 
Week 20 Week 36 
Rabbit 14 42 ng - - 1/16 (6.25%) 1/16 (6.25%) 
Rabbit 15 42 ng - - 4/16 (25%) 4/16 (25%) 
Rabbit 16 42 ng + + 0/16 (0) 0/16 (0) 
Rabbit 17 42 ng + + 1/16 (6.25%) 1/16 (6.25%) 
Rabbit 18 42 ng + + 2/16 (12.5%) 2/16 (12.5%) 
 
Four weeks after the first UVA/B radiation, we repeated the treatment (FIG 3.5.3 A). 
Unfortunately, one of the immunosuppressed rabbit 18 suddenly lost more than 20 % 
of body weight in one week after the UVA/B radiation for unknown reasons; therefore 
it was excluded from the experiment. Skin biopsies were taken 16 weeks post-
immunosuppression at latently infected sites and were analyzed by RT-qPCR. The 
results showed that there were 2 samples with higher viral copies (>1 copy/ cell) 
above the average (1 copy/ 500 cells). However, overall the viral DNA copy number 
in the taken samples showed no significant increase in the treated group compared 
to the controls (FIG 3.5.3 B). No papillomas appeared during the immunosuppression 
periods and following 5 months after cessation of immunosuppression.  
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3.6 The effect of immunosuppression on pre-existing papilloma 
growth 
3.6.1 The effect of immunosuppression on pre-existing papilloma growth 
During our pilot experiments of finding the optimal immunosuppression conditions, 
we observed that pre-existing papillomas grew much faster under CsA-based 
immunosuppressive treatment than the untreated controls (FIG S3). To confirm the 
observation, we carefully followed and measured the volume of single papillomas at 
FIG 3.5.3 Repeated treatment of CsA-based immunosuppression and UV radiation. (A) Schematic 
illustration of the experiment. (B) The quantification of CRPV DNA copy numbers in latently infected 
skin biopsies 16 weeks post immunosuppression. Each dot represents one sample. The data was 
log-transformed, and then the unpaired t-test was conducted for the statistical significant test. 
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all infected sites (Table 3.4.2). Papilloma sizes were measured weekly for 10 weeks. 
We observed that the dynamic growth of papillomas at all infected sites of the 3 
immunosuppressed rabbits (rabbit 11, 12 and 13) was significantly faster (FIG 3.6.1) 
compared to the non-immunosuppressed controls (rabbit 9 and 10). Despite under 
the same treatment, the papillomas on rabbit 13 appeared to have a slower growth 
rate compared to rabbit 12 and 11, but still significant faster compared to control 
rabbits (FIG 3.6.1 C). Rabbit 12 had to be euthanized in week 13 post-
immunosuppression due to an overburden of large papillomas (FIG 3.6.1 A, C). 
Furthermore, after the cessation of immunosuppression of rabbit 11 and 13, we 
observed the average volume of papillomas declined 25% within 8 weeks, then 
following constant normal growth speed (SGR: 4%/day) in the following 7 months of 
observation. When we reverted the experiment and immunosuppressed one of the 
control rabbit 9, we observed a significant increase in the volume of all papillomas 
within 8 weeks. The size of papillomas on the remaining control rabbit 10 showed no 
significant increase in the same period (FIG 3.6.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The figure is on the next page 
FIG 3.6.1 Drug-induced immunosuppression facilitates papilloma growth. (A) The growth curve of the 
average papilloma volume in the immunosuppressed group (rabbit 11, 12 and 13) and control group 
(rabbit 9 and 10). The numbers of papilloma measured for each rabbit were: 12 papillomas from rabbit 
9 and 10; 7 papillomas from rabbit 11; 13 papillomas from rabbit 12; 5 papillomas from rabbit 13. 
Rabbit 12 had to be euthanized after 13 weeks of immunosuppression due to the large sizes of 
papillomas. (B) The specific growth rate (SGR) of a single papilloma. Each dot in the graph represents 
the average SGR of one papilloma. The Mann-Whitney test was conducted for the statistical 
significant test. (C) The growth speed of papillomas in each rabbit. (D) Represent photos of non-
immunosuppressed rabbit (rabbit 9) and immunosuppressed rabbit (rabbit 12) after 13 weeks 
immunosuppression. 
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3.6.2 The effect of immunosuppression on viral DNA copies and E1^E4 
transcripts in papillomas.  
To determine whether immunosuppressant treatment contributes to viral infection, we 
quantified viral DNA copies and E1^E4 transcripts in papillomas. To do so, 
papillomas were surgically removed at 13 weeks post-immunosuppression (15 weeks 
p.i.) from both the immunosuppressed and the control rabbits, and subjected them to 
RT-qPCR analysis, the results showed that there were no significant differences in 
either the viral genome copy numbers (FIG 3.6.3 A) or E1^E4 expressions (FIG 3.6.3 
B) between the two groups.  
 
FIG 3.6.2 Reverse effect of immunosuppression or cessation of immunosuppression. After the 
cessation of the immunosuppression on rabbit 11 and 13, we observed a decreased volume of the 
papillomas within 8 weeks, and vice versa. When we started to immunosuppression on one of the 
control rabbit 9, we observed significant increase volume of papilloma in all infected sites. 
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3.6.3 The role of immunosuppression on immune response and T-cell 
cytotoxicity 
By FACS analysis, we found that the TLC, CD4+, and CD8+ cells were significantly 
decreased in PBMCs of rabbits that were immunosuppressed for 13 weeks (FIG 
3.6.4 A). In order to obtain a more detailed overview of the immune situation in 
immunosuppressed rabbits, we analyzed the expression of immune response-
associated cytokines both in the PBMCs and papillomas. Total RNA was isolated 
from PBMCs and papillomas 13 weeks after immunosuppression for the analysis of 
expression levels of cytokines associated with T-cells and cytotoxicity: Transforming 
FIG 3.6.3 Drug-induced immunosuppression does not influence viral genome copy numbers and 
viral gene expression within papillomas. (A) CRPV DNA copy numbers in papillomas of the control 
group (rabbit 9, 10) and in the immunosuppressed group (Rabbit 11, 12 and 13). There is no 
significant difference between these two groups. (B) The level of CRPV E1^E4 transcripts in 
papillomas of the control group and the immunosuppressed group. No significant difference was 
observed between these two groups. The Mann-Whitney test was conducted for the statistical 
significant test. 
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growth factor beta (TGF-β), interleukin 10 (IL-10), interferon γ (IFN- γ), interleukin 6 
(IL-6), interleukin 8 (IL-8), interleukin 17a (IL-17a), interleukin-1 beta (IL-1β), 
Chemokine (C-C motif) ligand 4 (CCL4), FAS-ligand (Fas-l), perforin 1 (Pfr-1), Tumor 
necrosis factor alpha (TNFα). The 2-∆∆cp method was used for RT-qPCR relative 
quantification. We found that the drug-induced immunosuppression broadly down-
regulated cytokines associated with T-cell response and cytotoxicity in both the 
PBMCs and in papillomas (FIG 3.6.4 B). However, there are exceptions, for instance, 
the expression of genes including IL8 and IL-1β, which were specifically up-regulated 
only in papilloma samples (FIG 3.6.4 B).  
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FIG 3.6.4 Gene expression profiles associated with T-cells and cytotoxicity. (A) FACS analysis of T 
cells in the PBMCs 13 weeks post immunosuppression. (B) The expression of cytokines in PBMCs 
versus papillomas 13 weeks post immunosuppression. The gene expression of cytokines of 
immunosuppressed group (rabbit 11, 12 and 13) was normalized to that of the non-
immunosuppressed control group (rabbit 9 and 10), respectively. P < 0.001: ***. 
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3.6.4 The effect of the immunosuppresive drugs on the rabbit cell proliferation 
in vitro.  
It has been shown that the immunosuppressant drugs such as CsA can induce in 
vitro cell proliferation and tumorigenesis independent of the immune system in 
different human-derived cells (178, 179). This experiment was designed to 
investigate the possible effect of immunosuppressant drugs on cell proliferation of 
rabbit-derived cell lines such as AVS cell line and Vx2 cell line. The 
immunosuppressant Sirolimus (SRL), known as an inhibitor of the mammalian target 
of rapamycin (mTOR), was used as a control.  
We first tested a therapeutic concentration 250 nM (0.3 ng/µL) CsA, 100nM (0.04 
ng/µL) Dex, and 100 nM (0.1 ng/µL) Sir on AVS cells growth, respectively as 
previously described (178, 180, 181). To do so, 5000 AVS cells in 100 µL KSFM with 
EGF and BPE were seeded in 24 well collagen I coated plates. Twenty-four hours 
after seeding, the culture medium was replaced by KSFM medium without BPE, or 
with BPE containing EGF, CsA, Dex, or SRL, respectively (FIG 3.6.5). Five days after 
treatment, cells were harvested and counted. The results showed that the treatment 
of CsA increased the AVS cells number compared to the treatment of EGF, Dex or 
SRL (FIG 3.6.5, FIG S4). 
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We next investigated the effect of the three immunosuppressants on cell proliferation 
using WST-1 assay. The results showed that CsA showed growth enhance effects on 
Vx2 cells at a concentration ranging from 0.1 ng/µL (83 nM) to 1 µg/µL (0.83 mM), 
whereas Dex and Sir showed no significant effect on Vx2 cell growth (FIG 3.6.6 A). 
In addition, CsA showed an enhanced effect on AVS cell growth at a concentration 
ranging from 0.1 ng/µL (83 nM) to 10 ng/µL (8.3 µM), whereas Dex and SRL showed 
growth inhibit effects (FIG 3.6.6 B).  
 
 
 
 
 
FIG 3.6.5 The effect of BPE, EGF, CsA, Dex, and SRL on rabbit derived cells (AVS) growth. BPE: 
Bovine Pituitary Extract; EGF: human recombinant Epidermal Growth Factor; CsA: Cyclosporine A; 
Dex: Dexmethasone; SRL: Sirolimus.  
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FIG 3.6.6 The effect of immunosuppressive drugs on rabbit derived cells growth. (A) Cell 
proliferation of Vx2 cells. (B) Cell proliferation of AVS cells. The light blue bar marks the range of 
therapeutic blood and drug concentrations in rabbits.  
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4 DISCUSSION 
In this study, we established an outbred CRPV/rabbit model to investigate whether 
latent cuHPVs infections are controlled by the immune system and/or UV radiation. 
We observed that a level of one viral DNA copy per 200 to 1000 cells can be 
detected in 88% of the latently infected skin sites more than 14 months p.i.. Viral 
copy numbers dramatically increased, when latent skin samples were explanted in 
tissue culture. We also observed an increase in viral genome copy numbers in 
latently infected skin sites remaining in the animal upon immunosuppression, but no 
increased tumor formation. Surprisingly, the combination of immunosuppression and 
UVA + UVB radiation showed no significant difference compared to 
immunosuppression alone. However, a dramatic increase of pre-existing papilloma 
growth was observed upon CsA-based immunosuppression. T-cell counts and T-cell 
associated cytokines were significantly decreased by immunosuppression. 
Interestingly, the pro-inflammatory cytokines such as IL-8 and IL-1β were significantly 
upregulated specifically in the fast growing papillomas. Furthermore, our results 
indicate that the proliferation of rabbit-derived cells was increased upon CsA 
treatment in vitro. 
4.1 A CRPV/rabbit model for cuHPV latency study 
The aim of this project was to optimize the CRPV model system in order to allow us 
to study the latent state of the cuHPV life cycle. The CRPV infection of domestic 
rabbits is the best model for studying cuHPV-associated disease (182), latent 
infections (109, 110), as well as malignant progression and testing 
immunotherapeutic strategies (107, 108). In a CRPV/rabbit model, the formation of 
papillomas is virtually completed by 10 weeks, and invasive malignant progression 
after 6 - 12 months post-infection (78, 134). 
The infection induced by either CRPV virions or viral DNAs in domestic NWZ rabbits 
is abortive (107). This has the advantage that the risk of new infections or 
reinfections during reactivation due to virus production and spread is eliminated. 
Moreover, we used tattoo ink for easy identification of previously infected tissues. We 
were subsequently able to harvest these sites and study them specifically in more 
detail. The highest efficiency of papilloma formation is obtained using a gene-gun 
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system for CRPV DNA inoculation (107). By using this system, we were able to 
quantify the exact amount of viral DNA being delivered using RT-qPCR and thus are 
able to evaluate the efficacy of the experiment (FIG 3.1.1A, Table S1). The infection 
of rabbits with CRPV is highly reproducible with almost all rabbits forming visible 
papillomas within 10 weeks. We used the out-bred NZW rabbits with different genetic 
background in this study to mimic the real situation in humans.  
Previous studies of CRPV infection of domestic Dutch-Belted rabbits demonstrated 
that a low-titer vrial infection (approximately 105 viral particles/1-cm2 site) resulted in 
asymptomatic infection with minimal spontaneous activation. Viral DNA could still be 
detected one-year p.i. (109, 110). In our studies of CRPV latent infection in domestic 
NZW rabbits, we observed similar results. Inoculation of low-dose CRPV DNA per 
site resulted in asymptomatic infection at the majority infected site (FIG 3.1.1B). 
Using our highly sensitive RT-qPCR method, we were able to examine CRPV DNA 
copy number at infected asymptomatic sites and in apparent papillomas. During a 
latent infection, there appeared to be no significant amplification of viral DNA (FIG 
3.1.2) and limited viral gene expression (Table 3.1.2), which is similar to that was 
found in the ROPV latent infection model (105). We also observed that the level of 
viral DNA detected at latently infected sites of our model system is relevant to that 
was found in the eyebrow hair of immunocompetent people (1 copy per 60 to 600 
cells) (68, 183).  
4.2 Possible factors that contribute to CRPV latent infection 
The skin cells are composed of multiple complex cell compartments such as cells of  
intermolecular epidermis, hair follicles (HF), sebaceous gland and immune system 
(76, 184). During the viral latency, most of the skin cells were uninfected, which may 
dilute out the latently infected cells. The low levels of latent viral copy number per cell 
in clinical rabbit skin biopsies may therefore not represent the true viral DNA copies 
per infected cell. However, when the infected skin biopsies were explanted ex vivo in 
suitable conditions, a higher copy number of viral DNAs was observed in the 
explanted cells (FIG 3.1.5). Although it is not clear which type of cells harbor latent 
viral DNAs in the skin, it is most likely that the CRPV latently infected cells are also 
present in HFs, as we have previously shown that during productive infection, the 
primary target cells of CRPV are located in self-renewable HF stem cells (78). 
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Additionally, we observed that a quarter of the explanted cells express one of the 
potential HF stem cell markers K15 (FIG 3.1.6). It has been shown that cells present 
in the bulge region of HFs can be quiescent for up to one year (185). It is possible 
that some viral DNA establishes long-term latent infection in the slow cycling 
quiescent stem cells. These cells are likely to be activated and undergo cell division 
or differentiation during normal homeostasis or wound repair resulting in an elevation 
of viral DNA copy numbers. Accordingly, cells harboring latent viral genome were 
likely to be activated from their quiescent state when explanted ex vivo resulting in a 
dramatic increase of viral copy numbers (FIG 3.1.5B).  
It is clearly shown in this study that unlike the latent infection with EBV and HIV (186, 
187), the latent CRPVs were not strictly regulated by levels of DNA CpG methylation 
in the host cells, since no CpG methylation has been found in the promoter region of 
CRPV latent viral genome (FIG 3.1.7). In addition, it is likely that some of the latent 
viral genomes stay episomal, as circular episomal viral DNA forms can be found and 
full-length E1 and E2 genes can be detected (FIG 3.1.9, 3.1.10). However, we cannot 
rule out the existence of potential integrated forms in the latently infected cells.  
Interestingly, one unexpected finding led us to identify whether the CRPV DNA was 
replicating in host cells. The dcm methylations are known in almost all commonly 
used cloning bacterial strains such as DH5α E. coli, which specifically methylates 
sequences which contain CCA/TGG (dcm) (173). In this study, the original CRPV 
DNA were amplified using DH5α E. coli, and we showed that the dcms of viral 
plasmid DNA were completely methylated (Table 3.1.3, FIG 3.1.8). Those dcm 
methylations were retained only in some of the sequenced clones from latently 
infected skin sites. However, most of the sequenced clones lost dcm methylations 
indicating that the viral DNAs were newly synthesized in the infected cells, which 
strongly argues that the latent viral genomes were replicating in the host cells. 
However, the results also showed that 34% to 48% of the original viral plasmid DNAs 
with dcm methylation were still retained for such long time in an unreplicated form 
more than 14 months p.i. (Table 3.1.3). The exact reason is unclear. As discussed 
previously, one possible explanation is that these original viral plasmid DNAs were 
maintained in the slow-cycling quiescent epidermal stem cells.  
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4.3 Low-dose UVB radiation showed no significant effect on 
papilloma formation and viral copy numbers 
UV light is believed to be an important risk factor for the development of beta-HPV 
associated cutaneous warts in immunocompetent general population (13, 69). The 
first evidence is shown by Zhang et al., (110) where UV radiation may facilitate low-
dose papillomavirus particle induced infection via induction of E6/E7 oncogenes 
expression. However, it is worth noting that in this previous study the UV treatment 
was performed two weeks after infection, which was during the incubation period of 
the development of a visible papilloma (usually take 7 to 10 weeks). From this data, it 
is not clear whether UV irradiation activates latent viral infection or facilitates the 
appearance of low-dose viral infections resulting in an increased formation of 
papillomas. Most recently, Uberoi et al., (75) demonstrated that UVB induces 
immunosuppression in immunocompetent mice that strongly correlates with the 
MmuPV1 induced papilloma formation.  
It is known that the E6 protein of cuHPV 8, 20, 22, 38, 76, 92 and 96 can inhibit 
apoptosis in response to UV-mediated damage in vitro (45, 58, 188). Several in vivo 
experiments have shown that the expression of the viral gene E2 (189), E6 (177) or 
all early genes (190) in K14HPV8 transgenic mice and E6 and E7 (191) in 
K14HPV38 transgenic mice contribute to the development of skin tumors following 
UV radiation. However, these observations remain controversial, because in these 
studies the viral genes are under the control of a heterologous UV-responsive 
keratin-14 promoter in the context of these transgenic mouse models, the 
physiological relevance of this observation is more related to an increase of viral 
transcription after UV radiation than to the effect of UV irradiation (75).  
On the contrary, using the outbred CRPV/rabbit system we observed a trend but no 
significant increasing of viral copy number after incubation period, and no significant 
effect on papilloma formation upon UV irradiation (FIG 3.2.2 and Table 3.2.1), as 
well as no effect on papilloma formation in latent stage (FIG 3.2.3 and Table 3.2.2). 
Though, it is possible that the intensity of UVB light we applied here was too low, or 
the reactivation of latent viral infection requires more repeated doses of UVB 
radiation.  
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In addition, It has been reported that latent PV DNA infections could be activated by 
mechanical irritations in a rodent Mastomys Natalensis laboratory animal model, 
which naturally carries an endogenous latent MnPV (192). However, our attempts to 
use mechanical irritation to reactivate CRPV latent infection were unsuccessful (FIG 
S2). Some possible explanations include, firstly, the mechanical irritation cannot be 
standardized, and the period of the treatment may have been too short compared to 
the MnPV experiment (67 weeks). Secondly, the number of reactivated latent 
infected sites may have been too small, which reduced the possibility of inducing new 
papillomas. Therefore, we are unable to make a clear statement as to whether the 
mechanical irritation could reactivate the latent CRPV infection or not. A further study 
should be designed to address this question. 
4.4 No increased tumor formation, but an increase of viral DNA 
copy numbers in latently infected skin sites upon 
immunosuppression 
Beta-HPV infections are common and mostly asymptomatic in the general population 
(12, 90, 91). Drug-induced immunosuppression post-transplantation led to the 
elevation of beta-HPV viral loads in most OTRs (68, 92, 93), which suggests that 
either reactivation of latent infection or increased susceptibility to new infections took 
place. Studies of ROPV infection in rabbits hint to the point that latent viral DNA can 
persist in the epithelial basal layer up to one year with limited viral transcriptions 
(105). However, drug-induced systematic immunosuppression showed an increase in 
latent viral copy numbers, but not significant effect on the ROPV latent infection in 
papilloma formation (only one papilloma appeared) (106). In addition, ROPV causes 
mucosotropic lesions in the back side tongue of rabbits, which regress in 100% with 
8 weeks p.i.. The results of the ROPV model may therefore not be applicable for the 
study of latent infections of cutaneous PVs.  
Most recently, in a MmuPV1 mouse model, the infection of the virus is species-
specific to individual mouse strains and the depletion of CD3+ cells permits efficient 
infection of non-susceptible mice. Neither the depletion of CD4+ nor CD8+ cells 
alone increased the susceptibility of MmuPV1 infections (121). Remarkably, Wang, et 
al., (122)  also showed no appearance of papillomas in CD4+ or CD8+ depleted mice 
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upon MmuPV1 infection, but the viral DNA can still be detected 5 weeks p.i.. When 
the either CD4+ or CD8+ depleted mice were treated with anti-CD3 antibody, 
papillomas significantly appeared in only the CD4+ depleted group (14/15) within ten 
weeks, but not in the CD8+ depleted group (1/15). Although the reason was not 
clear, the new appearance of papillomas is an indication of reactivation of latent 
infection from asymptomatic sites.  
In this study, we employed the outbred CRPV/rabbit model and administered 
immunosuppressive regimen to the latently infected rabbits, which is the closest 
system to the infection of cuHPV in OTRs. Using this latent model system we 
observed no increased tumor formation (FIG 3.4.3, Table 3.4.1), but an increase of 
viral DNA copy numbers in latently infected skin sites upon immunosuppression (FIG 
3.4.3 C). It is possible that reactivation of the latent infection may need longer-term of 
immunosuppression. Under chemical immunosuppression, we observed surprisingly 
three new papillomas that appeared more than 15 weeks p.i. (FIG 3.4.4), which might 
indicate that immunosuppression treatment could activate latent viral infection in 
some cases. Because CRPV infection of NZW rabbits does not result in virus 
production, we can rule out that, the new papillomas occurred due to an increased 
susceptibility to new infections. However, all three papillomas that appeared under 
immunosuppression were found only in one rabbit; and as out-bred rabbits were 
used in this CRPV-infection model, we cannot exclude that rabbit leukocyte antigen 
types may contribute to this effect. 
We also observed that the viral DNA mediated infection using Gene gun method 
showed no increased susceptibility upon immunosuppression either started 2 weeks 
prior infection or 2 weeks p.i. (Table 3.4.1, 3.4.2 and 3.4.3). One possible 
explanation is that the infection using viral DNA can be inhibited only by the cell-
mediated immune response because infection bypasses any effect of neutralizing 
antibodies, which are induced by primary infections with viral particles (107). At an 
early stage, the systematic immunosuppression might not increase the susceptibility 
of the viral DNA induced infection. 
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4.5 The combination of immunosuppression and UVA/B radiation 
showed no significant difference compared to immunosuppression 
alone 
In clinical observations, the presence of cuHPV associated warts appeared in 15% of 
renal transplant recipients (RTR) during the first year post-transplantation, 25% – 
42% within 3 years post transplantation, and 77% – 92% in 5 years post 
transplantation (62). UV light is believed to be an important risk factor for the 
development of cuHPV associated warts in RTRs, as most lesions appeared in sun-
exposed areas (13, 61). In addition, the cumulative incidence of SCCs steadily 
increased in RTRs over the years after the start of immunosuppression, e.g, it 
reaches 60% at 20 years in Australia with a high sunlight exposure (51, 193, 194), 
and only 20% in Norway with much less sunny climate (195). These observations 
indicate that systemic immunosuppression and UV light might work in synergy for 
reactivation of latent HPV infections. Therefore, we performed both 
immunosuppression and UVA/B irradiation to reactivate CRPV induced latent 
infections. Surprisingly, we observed no significant effect in terms of viral load or 
papilloma formations compared to immunosuppression alone (FIG 3.5.2, FIG 3.5.3, 
and FIG S5). The reason why the combination of these two factors had no significant 
effect is still unclear. One possibility is that the reactivation of latent viral infections 
may require prolonged immunosuppression (years) and multiple UV exposures. 
However, due to side effects of immunosuppressant drugs and UV radiations, it is 
difficult to achieve a long-term treatment using this animal model.  
4.6 CsA-based immunosuppression promotes pre-existing 
papilloma growth 
CsA, a well-known calcineurin inhibitor (CNI) that acts selectively on T cell activity, 
has long been used to prevent solid organ rejection in OTRs (196). In addition, it has 
also been approved for the treatment of diseases in dermatology such as psoriasis, 
atopic dermatitis, and blistering disorder by the US Food and Drug Administration in 
1997 (197, 198). For the immunosuppressive effect, “CsA forms a complex with 
cyclophilin, which inactivates calcineurin phosphorylase, preventing the 
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phosphorylation of NFATs and, therefore the transcription of interleukin-2 (IL-2). IL-2 
is required for full activation and proliferation of T-lymphocytes” (196, 197).  
It has been shown that the use of CsA in NZW rabbit not only led to 
immunosuppressive effect, but also cause many side effects such as loss of weight, 
reduced food and water consumption, and reduced movement (199). Reduction of 
CsA dose reduced toxicity, but at the expense of reduced immunosuppression (199). 
However, with a combination of corticosteroids drugs such as Dex resulted in 
effective immunosuppression effect and reduction of toxicity in a domestic rabbit 
(106). Systematic immunosuppression using CsA alone or combined with Dex 
delayed the spontaneous regression of papillomas induced either by CRPV or ROPV 
(106, 157).  
In this study, we observed that CsA combined with Dex treatment significantly 
facilitated the growth of pre-existing papillomas induced by CRPV in outbred NZW 
rabbits (FIG 3.6.1). Interestingly, cessation of immunosuppression resulted in 
shrinking of the fast growing papillomas but did not cause complete regression (FIG 
3.6.2). Our data shows that the fast-growing papillomas were not associated with the 
levels of viral DNA copies or viral gene expressions (FIG 3.6.3). We showed that that 
the reduction of cytotoxic CD8+ cells and downregulation of the expression of 
cytokines in papillomas might contribute to the increased growth of papilloma (FIG 
3.6.1). One possibility is that the reduction of cytotoxic CD8+ cells promotes 
papillomas growth, whereas the cessation of immunosuppression lead to the 
recovery of T-cells, which eliminated highly immunogenic tumor cells and left the low 
immunogenic tumor cells to grow at a normal speed (FIG 3.6.2, and 3.6.4). The 
broad downregulation of cytokines is another indication of significantly suppressed 
activity of T lymphocytes parallel to FACS analysis (FIG 3.6.4).  
Interestingly, of the cytokines examined in this study, the expression of IL-8 and IL-1β 
was specifically upregulated only locally in papillomas of immunosuppressed animals 
(FIG 3.6.4 B). It is known that IL-8 and IL-1β are type Th2 pro-inflammatory 
mediators, and their upregulation indicates severe chronic host inflammatory 
responses. IL-8 is a chemokine mainly produced by macrophages and other cell 
types such as keratinocytes. IL-8 function as a primary cytokine recruits neutrophils 
to the site of infection during the acute phase of inflammation. Increased expression 
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of IL-8 has been demonstrated in cancer cells, tumor-associated macrophages, 
endothelial cells, and infiltrating neutrophils, suggesting that IL-8 may function as a 
significant regulator factor within the tumor microenvironment. The expression of IL-8 
has also been correlated with angiogenesis, tumorigenicity, and metastasis of tumors 
in numerous xenograft and orthotopic in vivo models (reviewed in (200)). 
Accordingly, IL-1β, an important mediator of the inflammatory response, that is 
mainly produced by activated macrophages as a proprotein is involved in a variety of 
cellular activities such as cell proliferation, differentiation, and apoptosis. It has also 
been shown that IL-1β is abundant at tumor sites, where it may affect the process of 
carcinogenesis, tumor growth and invasiveness, as well as the patterns of tumor-host 
interaction (reviewed in (201)). It has been shown recently that increased local 
expression of IL-8 and IL-1β in the cervical region indicates the progression of 
cervical intraepithelial neoplasia lesions in Japanese patients (202). In contrast, most 
recently Martin Kast’s group reported that patients with “Treeman disease” have 
significantly reduced expression levels of IL-8 and IL-1β (HPV 2017 - Papillomavirus 
Conference, unpublished data). The Treemen disease is a condition associated with 
infection of HPV types 1 or 2 results in an uncontrolled “tree bark-like” growth and 
proliferation of infected keratinized epithelium in the hands and feet. It has been 
proposed that the causes of Treemen disease arises from a genetic defect that 
causes a potential immune deficiency related to Langerhans cell and innate skin 
immunity against HPV infection. However, this situation might differ from drug-
induced systematic immunosuppression, whereas T-cells were suppressed. 
Therefore, the increasing expression of IL-8 and IL-1β in papillomas of 
immunosuppressed animals might indicate the increasing activities of tumor 
associated marcrophages, which might be also an indicative of ongoing inflammation 
in the tumor microenvironment and possibly one of the causes of the fast growing 
papillomas. 
4.7 CsA treatment induce cell proliferation independent of 
immunosuppression  
It is believed that immunosuppression alone is not sufficient to promote SCC of the 
skin. For instance, it is well recognized that HIV-infected patients with profound 
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immune depletion, show a significantly lower incidence (4.11 fold) of SCC of the skin 
compared to OTRs (28.62 fold), arguing against a direct role of the immune system 
in malignant transformation of epidermal cells to cancer (203). OTRs treated with 
Tacrolimus, another CNI inhibitor, for immunosuppression had a lower incidence of 
SCCs post-transplantation than patients on CsA (204). There is compelling evidence 
that CsA causes increases in metastases of carcinoma in laboratory animals lacking 
an immune system (205). Additionally, immunosuppressant Sirolimus (SRL) inhibits 
the tumor promoting effects of CsA in such mice (206). On the other hand, it has 
been reported by numerous studies that CsA has pro carcinogenic effects, e.g. 
treatment of CsA lead to the activation of the proto-oncogene Ras (179), oncogene 
ATF3 (207, 208), TAK1/TAB1 pathway (209), AKT pathway (210), and mitochondrial 
reactive oxygen species (ROS) (178). Using a microarray analysis, Tiu et al., (211) 
demonstrated that the treatment of CsA in a cell line of SCC activates or inhibits a 
variety of genes important for cell-cycle regulation, apoptosis, and oncogene/ tumor-
suppressor activation. Above all, these studies indicate that CsA not only functions 
as an immunosuppressant on the immune system but also potentiates 
carcinogenesis independent of the immune system. However, the CsA-based 
immunosuppression has been used in all previous PV-related studies (106, 121, 157, 
212), and the direct effect of this immunosuppressant on PV-induced tumorigenesis 
has not been investigated. Here we demonstrated that CsA induces proliferations in 
rabbit-derived cells indicating a role that CsA might play in the direct tumorigenesis. 
Taken together, the fast growth of pre-existing papillomas may result from the 
involvement of multiple factors such as reduction of immune surveillance, 
upregulation of pro-inflammatory cytokines such as IL8 and IL-1β, and maybe CsA 
supported tumorigenesis.  
4.8 Outlook 
We established an outbred CRPV/rabbit model to investigate cutaneous PV latent 
infection. Our work not only has provided insights into the virus life cycle, but also 
opened avenues for further exploration that will help to answer some remained 
important questions. 
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4.8.1 Target epithelial stem cells of latent papillomavirus infection 
As discussed in section 4.2, based on our preliminary data we hypothesized that 
cells harboring latent CRPV genomes are a group of quiescent epithelial HF stem 
cells. However, it needs further investigation, e.g. identifying the direct association 
between latent viral genome and target stem cells. One approach is to use 
immunofluorescence combined with a LCM method to identify epithelial stem cells. A 
panel of antibodies should be used to detect the presence or absence of cellular 
proteins. In using such antibodies on rabbit skin dissections, it will be possible to 
identify cells that display these markers such as Lgr-5, K14, K15, CD34, CD200, or 
β1 integrin, and are therefore likely to be stem cells. Dissection of these cells by LCM 
followed by extraction of viral DNA and analysis by RT-qPCR will determine if CRPV 
DNA is present in these cells, but absent in cells lacking these markers. By targeting 
the infected cells, it will help us to investigate the viral life cycle under the latent state. 
However, during the course of this study these experiments could not be performed, 
due to lack of functional commercial primary antibodies against rabbits. 
4.8.2 Alternative long-term immunosuppression regimens 
We have observed that administration of CsA in NZW rabbit not only led to 
immunosuppressive effect, but also cause many side effects including loss of weight, 
reduced food and water intake. Although combination of Dex reduced such side 
effects, to achieve long-term (e.g. one year) immunosuppression remains a 
challenge. As we discussed in 4.5, accumulation of long-term immunosuppression 
might be required for reactivation of latent viral infections. Therefore, finding an 
alternative immunosuppression strategy is essential to answer the question. Possible 
immunosuppressant candidates such as SRL and Tacrolimus which are increasingly 
used in human transplant patients undergoing long-term immunosuppression as an 
alternative to CsA as it is less toxic and reduction of the incidence of carcinogenesis 
(196). Although, there is little research being done in rabbits in this regard, success 
has been achieved in mice (213). 
4.8.3 Investigate factors that contribute to pre-existing papilloma growth in vivo 
We observed that CsA-based immunosuppression led to fast-growing papillomas, 
and our results indicate that the proliferation of rabbit-derived cells was increased 
upon CsA treatment. Future studies should be designed to investigate whether the 
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fast growing papillomas are associated with the suppression of immune system 
and/or the drug-dependent manner in vivo. Evidences have been shown that 
immunosuppressant SRL reduces the incidence and progression of skin cancer, 
whereas CsA promote tumor growth and skin cancer in OTRs (214), as well as in 
mouse model (215). Studying the effect of immunosuppression induced by SRL or 
CsA on the pre-existing papilloma growth will help to answer the question. 
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5 CONCLUSION 
We have established an outbred CRPV/rabbit model for the study of latent infections 
with cutaneous papillomavirus which allows investigating factors controlling the latent 
state.  
We demonstrated that short-term immunosuppression increased latent viral genome 
copy numbers, but did not lead to new papilloma formation. Low-dose UV alone 
showed no significant effect on viral latency. The combination of short-term 
immunosuppression and UV radiation showed no significant difference compared to 
immunosuppression alone. However, it is still possible that the reactivation of latent 
viral infection may require longer-term systematic immunosuppression or multiple UV 
radiations. 
In addition, CsA-based immunosuppression facilitates pre-existing papilloma growth 
likely via reduction of immune surveillances, upregulation of pro-inflammatory 
cytokines such as IL8 and IL-1β, and maybe CsA related tumorigenesis 
Our findings here may provide implications for the clinic treatment of CsA-based 
immunosuppression of OTRs associated with cuHPV infection. 
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Table S1. Summary of the infection and outcomes of rabbits in this study. 
Rabbit ID in 
this thesis  
Infected 
doses  
(ng) * 
Number 
of 
infected 
sites 
Papilloma 
induction 
(positive/ 
total sites) 
Efficiency of 
papilloma 
induction 
Infection 
date 
Euthaniza- 
tion date 
Duration 
Months 
(M), Days 
(D) 
Rabbit 1 5700 4 3/4 75% 22.02.2013 19.02.2014 11M,28D 
330 8 7/8 87.5% 
170 8 7/8 87.5 
40 8 2/8 25% 
Rabbit 2 5700 4 4/4 100% 22.02.2013 02.10.2013 7M,10D 
330 8 8/8 100% 
170 8 8/8 100% 
40 8 3/8 37.5% 
Rabbit 3 5700 4 4/4 100% 23.02.2013 26.03.2014 13M,3D 
330 8 8/8 100% 
170 8 7/8 87.5% 
40 8 2/8 25% 
Rabbit LAT1 34 24 10/24 41.67%  28.10.2013 25.07.2014 8M, 28D 
Rabbit LAT2 34 24 2/24 8.33%  28.10.2013 22.06.2014 7M, 26D 
Rabbit LAT3 34 24 8/24 33.33%  29.10.2013 16.04.2015 17M, 19D 
Rabbit LAT4 34 24 5/24 20.08%  29.10.2013 08.06.2015 19M, 11D 
Rabbit 5  12  32 1/32 3.13%  04.09.2014 07.09.2016 24M, 4D 
Rabbit 6  12  32 3/32 9.38%  04.09.2014 07.09.2016 24M, 4D 
Rabbit 7  12  32 3/32 9.38%  19.09.2014 07.09.2016 23M, 20D 
Rabbit 8  12  32 1/32 3.13%  19.09.2014 07.09.2016 23M, 20D 
Rabbit 9  3800  16 13/16 81.25%  20.04.2015 02.06.2016 13M, 14D 
Rabbit 10  3800 16 16/16 100%  20.04.2015 02.05.2016 12M, 13D 
Rabbit 11  3800 16 9/16 56.25%  21.04.2015 02.05.2016 12M, 12D 
Rabbit 12  3800 16 13/16 81.25%  21.04.2015 28.07.2015 3M, 8D 
Rabbit 13  3800 16 6/16 37.5%  21.04.2015 18.08.2016 15M, 29D 
Rabbit 14  42 16 1/16 6.25%  05.05.2015 18.08.2016 15M, 14D 
Rabbit 15  42 16 4/16 25%  05.05.2015 18.08.2016 15M, 14D 
Rabbit 16  42 16 0/16 0  04.05.2015 13.04.2016 11M, 10D 
Rabbit 17  42 16 1/16 6.25% 04.05.2015 29.02.2016 9M, 6D 
Rabbit 18  42 16 2/16 12.5%  04.05.2015 18.08.2016 15M, 15D 
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FIG S1. RCA amplified CRPV DNA in latent skin biopsies. M: 1 kb maker, 1: RCA 
amplified CRPV-pLAII plasmid control, 2: RCA amplified Vx2 cell DNA extracts. 3 to 
20: RCA amplified DNAs from the latently infected site. All RCA amplified products 
were digested with SmaI for 4 hours and then were ran on 0.4% of agarose gel for 
1h. 
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FIG S2. Mechanical irritations of latent infection sites. (A) The irritations of latent 
infected skin on the tattoo ink marked areas where the viral DNA was inoculated. (B) 
The effect of mechanical irritations on latent viral copy numbers. Normal skin n = 8, 
before reactivation n= 10, after reactivation n= 13. The data was log-transformed, 
and then the unpaired t-test was conducted for the statistical significant test. 
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FIG S3. The pre-existing papillomas grew much faster upon drug-induced 
immunosuppression compared to the untreated control. (A) The growth curve of 
papillomas. The rabbit LAT1, LAT2 and LAT3 were immunosuppressed, whereas the 
rabbit LAT4 was non-immunosuppressed control. The rabbit 2 died due to 
unexpected lung infection 2 weeks post-immunosuppression. The average papilloma 
GMDs are significantly higher compared to that of the control rabbit. ***: p< 0.0001. 
(B) The representative photo of a papilloma on rabbit LAT1.  
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FIG S4. The effect of BPE, EGF, CsA, Dex, and Sir on rabbit-derived cells (AVS) 
growth. Photos were taken 5 days after incubation of a therapeutic concentration 250 
nM (0.3 ng/µL) CsA, 100nM (0.04 ng/µL) Dex, and 100 nM (0.1 ng/µL) Sir on AVS 
cells. 
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FIG S5. Comparison of latent viral copy number of immunosuppression alone with 
immunosuppression + UVA/B group. The samples for immunosuppression alone (n= 
12) were from rabbit 7 and 8 which under 17 weeks immunosuppression, whereas 
immunosuppression +UVA/B were from rabbit 16, 17 and 18 (n= 12) with 16 weeks 
immunosuppression. Each dot represents one sample. The data was log-
transformed, and then the unpaired t-test was conducted for the statistical significant 
test. 
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